Document:

TherapeuticsMD, Inc. 10-Q

Exhibit 10.1

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

 

 

COMMERCIAL
SUPPLY AGREEMENT

 

This Commercial
Supply Agreement (the “Agreement”) is made as of the 28th day of September, 2018, by and between
TherapeuticsMD, Inc., a Nevada corporation, with a place of business at 6800 Broken Sound Parkway NW, Third Floor, Boca
Raton, Florida 33487 (“TXMD”), and QPharma AB, a Sweden corporation, having a place of business at
Agneslundsvagen 27, Malmo, Sweden (“QPharma”).

 

Each
of QPharma and TXMD is sometimes referred to herein as a “Party” and collectively as the “Parties”.

 

RECITALS

 

A.            TXMD
is a company that develops, markets and sells pharmaceutical products;

 

B.             QPharma
is a developer and contract manufacturer of a variety of pharmaceutical products and medical devices including, but not limited
to, intra-vaginal devices eluting pharmaceutical substances;

 

C.             TXMD
is the exclusive licensee of the Population Council to commercialize in the United States a certain intra-vaginal ring system
eluting segesterone acetate and ethinyl estradiol;

 

D.            QPharma
is a qualified manufacturer of such intra-vaginal ring systems; and

 

E.             TXMD
desires to engage QPharma to manufacture and supply quantities of such intra-vaginal ring systems, and QPharma desires to manufacture
and supply such quantities of intra-vaginal ring systems, all pursuant to the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties
intending to be legally bound, hereby agree as follows:

 

ARTICLE
1

DEFINITIONS

 

The
following terms have the following meanings in this Agreement:

 

1.1           “Acknowledgement”
has the meaning set forth in Section 4.3.

 

1.2           “Affiliate(s)”
means, with respect to a referenced party, whether TXMD, QPharma or a third party, any corporation, firm, partnership or other
entity that controls, is controlled by or is under common control with such referenced party. For the purposes of this definition,
“control” means the ownership of at least 50% of the voting share capital of an entity or any other comparable
equity or ownership interest or possession of the right to control the management and policies of such entity.

 

    

    

    

 

1.3           “Agreement”
has the meaning set forth in the introductory paragraph, and includes all its Attachments and other appendices agreed to by the
parties (all of which are incorporated herein by reference) and any amendments to any of the foregoing made as provided herein
or therein.

 

1.4           “API(s)”
means the compounds segesterone acetate and ethinyl estradiol, as further described in the Specifications that either (i) have
been procured and released by TXMD and provided to QPharma or (ii) have been procured and released by QPharma, in either case
along with a certificate of analysis from the manufacturer of such compounds, as provided in this Agreement.

 

1.5           “Applicable
Laws” means, with respect to TXMD, all laws, ordinances, rules and regulations of each jurisdiction in which an API
or Product is produced, marketed, distributed, used or sold; and with respect to QPharma, all laws, treaties, or ordinances, rules,
regulations, cGMP, guidances, interpretations, authorizations, judgments, directives, injunctions, or orders of any court of any
international, national, regional, local, or other governmental body, agency, authority, or court, or arbitrator, that has jurisdiction
over the location where QPharma performs services, handles or stores an API, Raw Materials or Product, and manufactures Product
under this Agreement (and applicable cGMP), including, but not limited to, the Federal Food, Drug and Cosmetic Act and Good Laboratory
Practices, in each of the foregoing cases as in effect from time-to-time.

 

1.6           “Batch”
means a defined quantity of Product that has been or is being Processed in accordance with the Specifications in a single production
run. At the date of this Agreement, the theoretical size of a commercial validated Batch is approximately [***] units of Product.

 

1.7           “Components”
means the silicon ring system and other tangible elements incorporated into or packaged with the Product, but for the avoidance
of doubt, excluding APIs.

 

1.8           “cGMP”
means current Good Manufacturing Practices promulgated by the Regulatory Authorities in the jurisdictions included in Applicable
Laws (as applicable to TXMD and QPharma, respectively). In the United States, this includes 21 C.F.R. Parts 210, 211 and 820,
as amended from time-to-time, together with pertinent guidelines and guidance documents, and in the European Union, to the extent
applicable to the manufacture, handling and storage of the Product in Sweden for shipment to, and sale in, the United States,
2003/94/EEC Directive (as supplemented by Volume 4 of EudraLex published by the European Commission), as amended, Council Directive
90/385/EEC on Active Implantable Medical Devices (AIMDD)(1990) and Council Directive 93/42/EEC on Medical Devices (MDD) (1993),
as amended, supplemented and superseded from time-to-time, together with pertinent guidelines and guidance documents then in effect.

 

1.9           “Commencement
Date” means the first day of the Initial Pricing Term as established pursuant to Section 7.1, provided such date follows
approval by a Regulatory Authority of QPharma as a manufacturer of the Product.

 

1.10         “Confidential
Information” has the meaning set forth in Section 10.1.

 

1.11         “Contract
Year” means each consecutive twelve (12) month period beginning on the Commencement Date or anniversary thereof, as
applicable.

 

    2

    

    

 

1.12         “Defective
Product” has the meaning set forth in Section 5.2.

 

1.13         “Discloser”
has the meaning set forth in Section 10.1.

 

1.14         “Effective
Date” means July 26, 2018, [***].

 

1.15         “Exception
Notice” has the meaning set forth in Section 5.2.

 

1.16         “Facility”
means QPharma’s facility located in Malmo, Sweden, or such other facility as agreed by the parties in writing.

 

1.17         “Initial
Pricing Term” has the meaning set forth in Section 7.1.

 

1.18         “Initial
Term” means the period of time commencing as of July 26, 2018, and ending on July 26, 2024.

 

1.19         “Index”
has the meaning set forth in Section 7.2.

 

1.20         “Losses”
has the meaning set forth in Section 13.1.

 

1.21         “Marks”
means trademarks, trade names, service marks, logos and symbols.

 

1.22         “Process”
or “Processing” means the compounding, filling, manufacturing, producing, testing and packaging of APIs, TXMD-supplied
Materials, if any, and Raw Materials into Product by QPharma, and their handling, storage and delivery in accordance with the
Specifications and under the terms of this Agreement.

 

1.23         “Processing
Date” means the day on which the first step of physical Processing is scheduled to occur, as identified in an Acknowledgement.

 

1.24         “Process
Know-How” means all know-how provided by or on behalf of TXMD to QPharma and know-how to the extent it relates to the
processing, manufacture, quality control, formulation, filling, finishing, testing and packaging of a Product, whether in bulk
or final form, and regardless of container, including, without limitation, analytical tests methods for in-process and final Product,
copies of manufacturing records, formulation recipes, designs and drawings, and formulae, used in the Processing for a Product
to the extent it is in the possession, or under the control, of QPharma, its Affiliates and their respective subcontractors. For
the avoidance of doubt, such Process Know-How includes the Know-How TXMD obtained from The Population Council by operation of
TXMD’s acquisition of the Product’s New Drug Application under the License Agreement with The Population Council dated
August 1, 2018.

 

1.25         “Process
Know-How Transfer” means the commercially reasonable efforts of the parties undertaken pursuant to the Process Know-How
Transfer Plan to transfer copies of all Process Know-How (together with relevant books and records) and the “Standards”
(defined below) in QPharma’s possession or under its control, to TXMD as set forth in greater detail in the Process Know-How
Transfer Plan. As used herein “Standards” means data, information, or samples of validated or QPharma manufactured
or partially manufactured Product or other indicia measured at various points during Processing, to the extent QPharma possesses
such data, information, or samples.

 

    3

    

    

 

1.26         “Process
Know-How Transfer Plan” means that plan addressing orderly Process Know-How Transfer, to be prepared in writing and
reasonably agreed to by the parties within the sixty (60) day period following notice from TXMD to QPharma of its intention to
commence Process Know-How Transfer.

 

1.27         “Product”
means a silicon-based removable intra-vaginal ring system eluting segesterone acetate and ethinyl estradiol meeting the Specifications.

 

1.28         “Product
Maintenance Services” has the meaning set forth in Section 2.2.

 

1.29         “Purchase
Order” has the meaning set forth in Section 4.3.

 

1.30         “QPharma”
has the meaning set forth in the introductory paragraph, or any successor or permitted assign. QPharma shall have the right to
cause any of its Affiliates, upon prior written notice to and approval from TXMD, to perform any of its obligations hereunder,
and TXMD upon its prior approval of the use of such an Affiliate, shall accept such performance as if it were performance by QPharma,
but QPharma shall remain jointly and severally liable for the performance by any of its Affiliates under this Agreement.

 

1.31         “QPharma
Defective Processing” has the meaning set forth in Section 5.2.

 

1.32         “QPharma
Indemnitees” has the meaning set forth in Section 13.2.

 

1.33         “Qualified
Person (QP)” means a company employee that fulfils the requirements as described in European Directive 2001/83(2)/EC.
These requirements include personal qualities of integrity, maturity, open-mindedness, assertiveness, sound analytical skills
and judgment as well as a level of education, combined with practical work experience within pharmaceutical development, manufacture,
or Quality Assurance. The regulations specify that no batch of medicinal product can be released for sale or supply prior to certification
by a QP that the batch is in accordance with the relevant requirements.

 

1.34         “Quality
Agreement” has the meaning set forth in Section 9.7.

 

1.35         “Raw
Material(s)” means any and all raw materials, supplies, Components and packaging necessary to manufacture and ship Product
in accordance with the Specifications, but excluding the APIs and TXMD-supplied Materials, if any.

 

1.36         “Recall”
has the meaning set forth in Section 9.5.

 

1.37         “Recipient”
has the meaning set forth in Section 10.1.

 

1.38         “Regulatory
Approval” means any approvals, permits, product and/or establishment licenses, registrations or authorizations, including
approvals pursuant to U.S. Investigational New Drug Applications, New Drug Applications and Abbreviated New Drug Applications,
as applicable, of any Regulatory Authorities that are necessary or advisable in connection with the development, manufacture,
testing, use, storage, exportation, importation, transport, promotion, marketing, distribution or sale of APIs or Product in the
Territory.

 

    4

    

    

 

1.39         “Regulatory
Authority” means the international, federal, state or local governmental or regulatory bodies, agencies, departments,
bureaus, courts or other entities in the Territory that are responsible for (A) the regulation (including pricing) of any aspect
of pharmaceutical or medicinal products intended for human use including, but not limited to, their manufacture, handling and
storage, or (B) health, safety or environmental matters generally. In the United States, this includes the United States Food
and Drug Administration.

 

1.40         “Representatives”
of an entity mean such entity’s duly-authorized officers, directors, employees, agents, accountants, attorneys or other
professional advisors.

 

1.41         “Review
Period” has the meaning set forth in Section 5.2.

 

1.42         “Risk
Mitigation Plan” has the meaning set forth in Section 16.5(B).

 

1.43         “Specifications”
means the procedures, requirements, standards, quality control testing and other data and the scope of services as set forth in
Attachment A, as modified from time to time in accordance with Article 8.

 

1.44         “Term”
has the meaning set forth in Section 16.1.

 

1.45         “Term
Sheet” means that certain Binding Pricing Term Sheet for Supply of Product entered into on [***], between TherapeuticsMD
and QPharma.

 

1.46         “Territory”
means the United States of America, its territories, insular possessions and commonwealths.

 

1.47         “TXMD”
has the meaning set forth in the introductory paragraph, or any successor or permitted assign.

 

1.48         “TXMD
Equipment” means the equipment listed on Attachment B, together with all diagrams, schematics, operator’s
manuals, operating software and warranties.

 

1.49         “TXMD
Indemnitees” has the meaning set forth in Section 13.1.

 

1.50         “TXMD
IP” has the meaning set forth in the Development Agreement.

 

1.51         “TXMD-supplied
Materials” means materials to be supplied by or on behalf of TXMD to QPharma, other than APIs, for Processing, if any.

 

1.52         “Unit
Pricing” has the meaning set forth in Section 7.1(A).

 

1.53         “Validation
Plan” has the meaning set forth in Section 7.7.

 

1.54         “Vendor”
has the meaning set forth in Section 3.1(B).

 

    5

    

    

 

ARTICLE
2

PROCESSING
& RELATED SERVICES

 

2.1           Supply
and Purchase of Product. QPharma shall Process Product and deliver the same to TXMD, its Affiliates and licensees in accordance
with the Specifications, Applicable Laws and the terms and conditions of this Agreement.

 

2.2           Product
Maintenance Services. TXMD will receive the following product maintenance services (the “Product Maintenance Services”):
one annual audit (as further described in Section 9.5); regulatory audits (as further described in Section 9.4); one annual Product
review (within the meaning of 21 CFR § 211.180); access to document library over and above the Quality Agreement, including
additional copies of Batch paperwork or other Batch documentation; assistance in preparing Regulatory Approvals; Product document
and sample storage relating to cGMP requirements; vendor re-qualification; and maintenance, updates and storage of master batch
records and audit reports. For avoidance of doubt, the following services and items are not included in Product Maintenance Services:
technology transfer; analytical work; stability; and process rework.

 

2.3           Other
Related Services. QPharma shall provide such Product-related services, other than Processing or Product Maintenance Services,
as agreed to in writing by the parties from time to time. Such writing shall include the scope and fees for any such services
and be appended to this Agreement. The terms and conditions of this Agreement shall govern and apply to such services.

 

2.4           Validation
Services. QPharma operates a validated Process for the production of the Product, and will continue to do so.

 

ARTICLE
3

API,
MATERIALS & EQUIPMENT

 

3.1          The
APIs and Raw Materials.

 

A.            TXMD
shall be responsible for establishing a source of supply of the APIs. TXMD, at its option, shall enable QPharma to place orders
for the API’s from such source of supply. QPharma shall be responsible for inspecting and releasing adequate quantities
of the APIs and Raw Materials as necessary to meet the Firm Commitment, unless otherwise agreed to by the parties in writing.
QPharma shall not be liable for any delay in delivery of Product if (i) TXMD is unable to obtain, in a timely manner, a particular
API or (ii) QPharma is unable to obtain, in a timely manner, a particular API through its placement of orders therefor from TXMD’s
source of supply or Raw Material necessary for Processing and (iii) QPharma placed orders for such API or Raw Material promptly
following receipt of TXMD’s Firm Commitment. In the event that any API or Raw Material becomes subject to purchase lead
time beyond the Firm Commitment time frame, the parties will negotiate in good faith an appropriate amendment to this Agreement.
TXMD shall reimburse to QPharma its cost for the APIs. QPharma shall provide a credit to TXMD in the amount of any credit received
by QPharma from an API supplier resulting from a pricing agreement with such supplier, with such credits to be applied to the
next invoice issued thereafter to TXMD and successive invoices until fully expended. In order to facilitate the ordering and delivery
of initial supplies of APIs to QPharma, TXMD, in consultation with QPharma, may purchase supplies of APIs for delivery to QPharma.
Further, in order to facilitate the timely manufacture of Product for the Firm Commitment, QPharma shall maintain a safety stock
of APIs and Raw Materials. Such safety stock shall be in an amount mutually agreed to by the Parties. TXMD shall be responsible
for payment of the purchase price of any such APIs so ordered by it for delivery to QPharma.

 

    6

    

    

 

B.             In
certain instances, TXMD may require a specific supplier, manufacturer or vendor (“Vendor”) to be used for a
Raw Material. In such an event occurring after the date of this Agreement, such Vendor will be identified in the Specifications.
If the cost of such Raw Material from any such Vendor is greater than QPharma’s costs for the same Raw Material of equal
quality from other vendors, QPharma shall add the difference between QPharma’s cost of such Raw Material and the Vendor’s
cost of the Raw Material to the Unit Pricing. TXMD will be responsible for all costs associated with qualification of any Vendor
specifically required to be used upon written instruction from TXMD, which Vendor has not been previously qualified by QPharma.

 

C.             In
the event of (i) a Specification change for any reason, (ii) obsolescence of any API or Raw Material or (iii) termination or expiration
of this Agreement, TXMD shall bear the cost of any unused API or Raw Materials (including packaging), so long as QPharma purchased
such API and Raw Materials in quantities consistent with TXMD’s most recent Firm Commitment and the vendor’s minimum
purchase obligations. Such APIs and Raw Material shall be the property of TXMD upon payment therefor.

 

3.2          Supply
of Materials.

 

A.            TXMD
shall supply to QPharma for Processing, at TXMD’s cost, all TXMD-supplied Materials set forth on Attachment C, if
any, in quantities sufficient to meet TXMD’s requirements for Product. TXMD shall deliver such items and associated certificates
of analysis to the Facility no later than [***] ([***]) days before the Processing Date. TXMD’s failure to fulfill the foregoing
obligations in this Section 3.2 shall not by itself give rise to a cause of action in QPharma or a right by it to terminate this
Agreement. However, QPharma shall not be held liable for a delayed Processing Date related to TXMD’s own delay in delivering
TXMD supplied Materials and associated certificates to the Facility. TXMD shall be responsible at its expense for securing any
necessary DEA, export or import, similar clearances, permits or certifications required in respect of such supply. QPharma shall
use such items solely for Processing. Prior to delivery of any such items, TXMD shall provide to QPharma a copy of all associated
material safety data sheets, safe handling instructions and health and environmental information and any Regulatory certifications
or authorizations that may be required under Applicable Laws with respect thereto, and shall promptly provide any updates thereto.

 

B.             Following
receipt of TXMD-supplied Materials, QPharma shall inspect, test and release such items employing such measures as are set forth
in the Specifications. QPharma will receive, handle, store and use all TXMD-supplied Materials in compliance with all Applicable
Laws and labeled storage requirements, or lacking labeled storage requirement, the written instructions of TXMD, as agreed to
by QPharma, such agreement not to be unreasonably withheld. In the event that QPharma detects a nonconformity with Specifications,
QPharma shall give TXMD prompt notice of such nonconformity. QPharma shall not be liable for any defects in TXMD-supplied Materials,
or in Product resulting from defective TXMD-supplied Materials, unless QPharma failed to properly perform the foregoing obligations.
QPharma shall follow TXMD’s reasonable written instructions in respect of return or disposal of defective TXMD-supplied
Materials, at TXMD’s cost.

 

    7

    

    

 

C.             TXMD
shall retain title to TXMD-supplied Materials at all times and shall bear the risk of loss thereof, except for losses to the extent
due to the negligent acts or omissions of QPharma or QPharma’s failure to follow storage and handling requirements or mutually
agreed to written instructions of TXMD, in each case, subject to Article 14.

 

3.3          Artwork
and Labeling. TXMD shall provide or approve, prior to the procurement of applicable Raw Materials, all artwork, advertising
and labeling information necessary for Processing, if any. Such artwork, advertising and labeling information is and shall remain
the exclusive property of TXMD, and TXMD shall be solely responsible for the content thereof. Hence, TXMD will be responsible
for the artwork and labelling information communicated to QPharma for Processing and ensure itself that the latter comply with
provided text and relevant applicable laws and regulations prevailing in the Territory. Such artwork, advertising and labeling
information or any reproduction thereof may not be used by QPharma in any manner other than performing its obligations hereunder.

 

3.4          TXMD
Equipment. QPharma hereby acknowledges that the TXMD Equipment is the sole and exclusive property of TXMD, and is in the possession
of QPharma. During the Term, except as set forth below, QPharma shall be entitled to use the TXMD Equipment in the performance
of its obligations to TXMD pursuant to this Agreement. QPharma (i) shall mark the TXMD Equipment so as to identify it as the property
of TXMD, (ii) shall safeguard the TXMD Equipment with the same degree of care as it uses in connection with the safeguarding of
its own equipment and (iii) shall be responsible for the proper operation, maintenance and repair of the TXMD Equipment. QPharma
shall not sell, lease or lend the TXMD Equipment to any third party or relinquish possession or control of the TXMD Equipment.
QPharma shall not move the TXMD Equipment from its current location without the advance written consent of TXMD. QPharma shall
not grant a security interest in, use as collateral or otherwise encumber the TXMD Equipment in any way, or suffer the placement
of a lien or other security device upon the TXMD Equipment. Upon request of TXMD, whether at the expiration of the Term or prior
thereto, QPharma shall promptly make the TXMD Equipment ready for removal by TXMD or its designees, and shall grant access to
TXMD and its designees to QPharma facilities for the purpose of such removal. During the Term, in the event, and to the extent,
there exists capacity in the use of the TXMD Equipment in excess of its use to fulfill purchase orders of TXMD, QPharma may use
the TXMD Equipment for its intended purpose in the performance of its manufacturing obligations for The Population Council, Inc.
or its designee.

 

3.5          Additional
Manufacturing Line. In order to plan for and meet potential demand for the Product in excess of QPharma’s current capacity,
the Parties will prepare and reasonably agree to a manufacturing capacity expansion plan within ninety (90) days of the date of
this Agreement, such plan to address the actions to be taken, the equipment to be purchased and installed, and financial responsibility
therefor, along with a timeline, headcount plan, budget and assignment of responsibilities in the implementation of a second manufacturing
line and other capacity improvements, all as set forth in such plan. For the avoidance of doubt, the Additional Manufacturing
Line will also be comprised of TXMD Equipment.

 

    8

    

    

 

ARTICLE
4

PURCHASE
ORDERS & RELATED MATTERS

 

4.1          Purchase
Order Requirement. No purchase order shall be submitted for less than [***] commercial validated [***]. Purchase orders reflecting
purchases in excess of [***] shall be submitted only in [***] Batch multiples.

 

4.2          Guidance.
TXMD shall keep QPharma generally informed of its anticipated need for Product, including anticipated launch quantities, through
delivery of a summary report every [***] ([***]) months. The parties shall cooperate in an effort to provide for an orderly process
of purchase order submissions and deliveries of Product.

 

4.3          Purchase
Orders.

 

A.            As
provided in this Section 4.3(A), TXMD shall submit to QPharma a binding, non-cancelable purchase order for Product specifying
the number of Batches to be Processed, the Batch size (to the extent the Specifications permit Batches of different sizes) and
the requested delivery date for each Batch (“Purchase Order”).

 

B.             Promptly
following receipt of a Purchase Order, QPharma shall issue a written acknowledgement (“Acknowledgement”) that
it accepts or rejects such Purchase Order. Each acceptance Acknowledgement shall either confirm the delivery date set forth in
the Purchase Order or set forth a reasonable alternative delivery date, and shall include the Processing Date. QPharma may reject
any Purchase Order not given in accordance with this Agreement; provided, however, QPharma shall accept any Purchase Order that
meets the requirements of this Agreement.

 

C.             In
the event of a conflict between the terms of any Purchase Order or Acknowledgement and this Agreement, the terms of this Agreement
shall control. No Purchase Order, confirmation, shipping document, receipt or similar document shall amend any term set forth
in this Agreement or set forth any term inconsistent with the terms and conditions contained in this Agreement.

 

4.4          QPharma’s
Cancellation of Purchase Orders. Notwithstanding Section 4.5, QPharma reserves the right to cancel all, or any part of, a
Purchase Order upon written notice to TXMD, and QPharma shall have no further obligations or liability with respect to such Purchase
Order, if TXMD refuses or fails to timely supply conforming TXMD-supplied Materials in accordance with Section 3.2. Any such cancellation
of Purchase Orders shall not constitute a breach of this Agreement by QPharma. QPharma shall use reasonable efforts to re-schedule
Processing reflected on such Purchase Order promptly after conforming TXMD-supplied Materials are delivered to QPharma.

 

    9

    

    

 

4.5           TXMD’s
Modification or Cancellation of Purchase Orders. TXMD may modify the delivery date or quantity of Product in a Purchase Order
only by submitting a written change order to QPharma at least [***] ([***]) days in advance of the earliest Processing Date covered
by such change order. Such change order shall be effective and binding against QPharma only upon the written approval of QPharma.
QPharma shall endeavor in good faith to mitigate the costs of such change order, but TXMD shall be responsible to QPharma for
unavoidable costs, including those resulting from non-cancellable contracts entered into by QPharma in good faith.

 

4.6           Unplanned
Delay or Elimination of Processing. QPharma shall use commercially reasonable efforts to meet the Purchase Orders, subject
to the terms and conditions of this Agreement. QPharma shall provide TXMD with as much advance notice as practicable if QPharma
determines that any Processing will be delayed or eliminated for any reason.

 

4.7           Observation
of Processing. In addition to TXMD’s audit right pursuant to Section 9.5, TXMD may send up to [***] ([***]) Representatives
to the Facility to observe Processing. Provided that QPharma has given TXMD adequate notice of commencement of Processing, TXMD
shall give QPharma written notice of its intention to observe processing at least [***] ([***]) days prior to the date of its
visit. The foregoing limitations shall not apply to time spent by TXMD Representatives on site at the Facility to participate
in or witness research and development activities or to witness Processing of validation Batches of Product. Such Representatives
shall abide by all QPharma safety rules and other applicable employee policies and procedures, and TXMD shall be responsible for
such compliance. TXMD shall indemnify and hold harmless QPharma for any action, omission or other activity of such Representatives
while on QPharma’s premises. TXMD’s Representatives who are not employees of TXMD shall be required to sign QPharma’s
standard visitor confidentiality agreement prior to being allowed access to the Facility. QPharma shall not be required to accommodate
any observation request or activity that would violate GMP or Swedish law. TXMD acknowledges that space constraints at QPharma’s
facilities also may limit its ability to observe.

 

ARTICLE
5

TESTING;
RELEASE

 

5.1           Batch
Release. After QPharma completes Processing of a Batch, QPharma shall also provide TXMD or its designee with QPharma’s
certificate of analysis, certificate of compliance and Qualified Person release for such Batch. Issuance of a certificate of analysis,
executed batch records and a certificate of compliance by QPharma constitutes release of the Batch by QPharma to TXMD. TXMD shall
be responsible for final release of Product to the market.

 

5.2           Testing;
Rejection. No later than [***] days after receipt of the Batch (“Review Period”), TXMD or its designee
shall notify QPharma whether the Batch conforms to Specifications. Upon receipt of notice from TXMD that a Batch meets Specifications,
or upon failure of TXMD to respond by the end of the Review Period, the Batch shall be deemed accepted by TXMD and TXMD shall
have no right to reject such Batch other than for defects which existed at the time of delivery and were not discovered or discoverable
in the exercise of reasonable care (“Latent Defects”). For the avoidance of doubt, (i) Batches failing to meet
Specifications at the time of delivery due to Latent Defects may be rejected, if at all, only upon notice to QPharma within [***]
([***]) days following the date on which such Latent Defect was discovered or should have been discovered in the exercise of reasonable
care and (ii) in no event may TXMD reject Product after such Product’s expiration date. If TXMD or its designee timely notifies
QPharma in writing (an “Exception Notice”) that a Batch does not conform to the Specifications or otherwise
does not meet the warranty set forth in Section 12.1(A), whether due to a Latent Defect or otherwise (“Defective Product”),
and provides a sample of the alleged Defective Product, QPharma shall conduct an appropriate investigation in its discretion to
determine whether or not it agrees with TXMD that Product is Defective Product and to determine the cause of any nonconformity.
If QPharma agrees that Product is Defective Product and determines that the cause of nonconformity is attributable to QPharma’s
failure to perform the Processing in accordance with the Specifications (“QPharma Defective Processing”), then
Section 5.4 shall apply. For avoidance of doubt, where the cause of nonconformity cannot be determined or assigned, it shall be
deemed not QPharma Defective Processing. For the avoidance of doubt, the Processing of any Batch that does not proceed to completion
or any Batch that does not pass release testing by QPharma shall be treated as Defective Product resulting from QPharma Defective
Processing. In such case, the remedies set forth in Section 5.4 shall apply.

 

    10

    

    

 

5.3           Discrepant
Results. If the parties disagree as to whether Product is Defective Product and/or whether the cause of the nonconformity
is QPharma Defective Processing, and this is not resolved within [***] days of the Exception Notice date, the parties shall cause
a mutually acceptable independent third party to review records, test data and to perform comparative tests and/or analyses on
samples of the alleged Defective Product and its components, including TXMD-supplied Materials. The independent party’s
results as to whether or not Product is Defective Product and the cause of any nonconformity shall be final and binding. Unless
otherwise agreed to by the parties in writing, the costs associated with such testing and review shall be borne by QPharma if
Product is Defective Product attributable to QPharma Defective Processing, and by TXMD in all other circumstances. TXMD will be
apprised in writing of all Defective Product investigations executed by QPharma on TXMD’s materials/products, including
Product and TXMD-supplied Materials, as well as final investigation outcome and conclusion(s).

 

5.4           Defective
Processing. QPharma shall, at TXMD’s option, either (A) replace at its cost another Batch of Product (as a replacement
for any Batch of Defective Product attributable to QPharma Defective Processing) using TXMD-supplied Materials provided at QPharma’s
cost, if any such items are required or (B) credit any payments made by TXMD for such Batch. THE OBLIGATION OF QPHARMA TO REPLACE
QPHARMA DEFECTIVE PROCESSING IN ACCORDANCE WITH THE SPECIFICATIONS OR CREDIT PAYMENTS MADE BY TXMD FOR DEFECTIVE PRODUCT ATTRIBUTABLE
TO QPHARMA DEFECTIVE PROCESSING SHALL BE TXMD’S SOLE AND EXCLUSIVE REMEDY UNDER THIS AGREEMENT FOR DEFECTIVE PRODUCT (APART
FROM RECALL COSTS SET FORTH IN SECTION 9.6, AND IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED).

 

ARTICLE
6

DELIVERY

 

6.1           Delivery.
QPharma shall deliver Product ExWorks (Incoterms 2010) at the Facility promptly following TXMD’s approval and notification
to QPharma’s to release the Product; provided, however, QPharma shall be responsible for loading the Product on the carrier’s
vehicle using due care. QPharma shall segregate and store all Product until tender of delivery. Title to Product shall transfer
to TXMD upon such delivery. TXMD shall qualify at least [***] ([***]) carriers to ship Product and then designate the priority
of such qualified carriers to QPharma.

 

    11

    

    

 

6.2          Storage.
Any items temporarily stored at QPharma shall be stored in compliance with requirements set forth in the Specification, or if
no such storage Specification exists for such item, QPharma shall store such items using due care taking into account the identity
of such item.

 

6.3          Subcontracting.
QPharma may utilize third parties to provide any part of the Processing only with the prior written approval of TXMD, provided
that the foregoing will not apply to generally available goods and services or to subcontracting to QPharma Affiliates. If TXMD
approves a subcontractor, then QPharma shall enter a written agreement with such subcontractor that enables QPharma to comply
with its obligations under this Agreement and places such subcontractors under obligations of confidentiality, non-use and intellectual
property ownership no less burdensome than those set forth herein and applicable to QPharma. QPharma will oversee all services
performed by any subcontractor, and will be responsible for such services as if such services were performed by QPharma. QPharma
shall remain liable for the performance of its subcontractors under this Agreement. The use of subcontractors shall not relieve
QPharma of any responsibility under this Agreement.

 

ARTICLE
7

PAYMENTS

 

7.1          Fees.
In consideration for QPharma performing services hereunder:

 

A.            TXMD
shall pay QPharma the unit pricing for Product set forth on Attachment D (“Unit Pricing”), which shall be in
effect for the period ending on (i) the third anniversary of delivery by QPharma of the first commercial Batch of Product to or
for TXMD; provided launch occurs on or before [***], or (ii) [***], if there is no such launch on or before [***] (the “Initial
Pricing Term”). QPharma shall sell and deliver Product in final dosage form, packaged for end user use. QPharma shall
submit an invoice to TXMD for such fees upon tender of delivery of Product as provided in Section 6.1.

 

B.             Other
Fees. TXMD shall pay QPharma for all other fees and expenses of QPharma owing in accordance with the terms of this Agreement,
including pursuant to Sections 2.3 and 4.1. QPharma shall submit an invoice to TXMD for such fees as and when appropriate.

 

7.2          Unit
Pricing Increase. After the Initial Pricing Period, the Unit Pricing may be adjusted on an annual basis, effective on each
July 1st (with the first possible price adjustment to be effective on July 1, 2021), upon [***] days’ prior written notice
from QPharma to TXMD, to reflect increases in labor, utilities and overhead and shall be in an amount equal to the change in the
Producer Price Index (the “Index”), “Pharmaceutical Preparation Manufacturing” (Series ID: PCU325412325412),
not seasonally adjusted, as published by the U.S. Department of Labor, Bureau of Labor Statistics. The initial base period for
comparison shall be the twelve (12) month period ending on June 30 immediately preceding the expiration of the Initial Pricing
Period. For the avoidance of doubt, if launch of the Product occurs on or after [***], but before [***], QPharma shall be entitled
to adjust Unit Pricing for the Initial Pricing Period based upon the difference in the Index on [***] and on [***], but not to
exceed [***] percent ([***]%). For the further avoidance of doubt, Unit Pricing Increases after the Initial Pricing Period shall
not exceed [***] percent ([***]%) in the aggregate for the Index. In addition, price increases (or decreases) for APIs and Raw
Materials shall be passed through at cost to TXMD and not included in the Index-based price adjustment described above.

 

    12

    

    

 

7.3           Payment
Terms. All QPharma invoices shall be due [***] ([***]) days after the date of receipt of invoice. No invoice shall be issued
to TXMD for Processing until the Batch so Processed has been released pursuant to Section 5.1; provided, however, with respect
to purchase orders for the initial [***] ([***]) Batches ordered by TXMD pursuant to this Agreement (the “Initial Batches”),
QPharma shall be entitled to issue invoices to TXMD upon receipt of such purchase orders in a non-refundable pre-paid amount equal
to [***] percent ([***]%) of the price of each such purchase order. Purchase orders for the Initial Batches shall be placed only
for even numbers of Batches to be Processed. Under a given purchase order covering some or all of the Initial Batches, TXMD shall
pay for all Batches released pursuant to Section 5.1, but shall first receive a credit in the amount of the pre-payment made pursuant
to such purchase order. If more than [***] percent ([***]%) the Batches Processed pursuant to a given purchase order for the Initial
Batches fail release pursuant to Section 5.1, QPharma nevertheless shall be entitled to retain the pre-payment made in respect
of such purchase order. TXMD shall make payment in U.S. dollars, and otherwise as directed in the applicable invoice. If any payment
is not received by QPharma by its due date, then QPharma may, in addition to any other remedies available at equity or in law,
charge interest on the outstanding sum from the due date (both before and after any judgment) at [***]% per month until paid in
full (or, if less, the maximum amount permitted by Applicable Laws).

 

7.4           Advance
Payment. Notwithstanding any other provision of this Agreement, if at any time TXMD is in arrears in paying amounts due under
this Agreement, QPharma may require payment in advance before performing any further services or making any further shipment of
Product. If TXMD shall fail, within a reasonable time, to make such payment in advance, or if TXMD shall fail to make any payment
when due, QPharma shall have the right, at its option, to suspend any further performance hereunder until such default is corrected,
without thereby releasing TXMD from its obligations under this Agreement.

 

7.5           Taxes.
All taxes, duties and other amounts assessed (excluding tax based on net income and franchise taxes) on TXMD-supplied Materials,
services or Product prior to or upon provision or sale to QPharma or TXMD, as the case may be, are the responsibility of TXMD,
and TXMD shall reimburse QPharma for all such taxes, duties or other expenses paid by QPharma or such sums will be added to invoices
directed at TXMD, where applicable.

 

7.6           TXMD
and Third Party Expenses. Except as may be expressly covered by Product Maintenance Service fees, TXMD shall be responsible
for 100% of its own and all third-party expenses associated with the development, Regulatory Approvals and commercialization of
Product, including regulatory filings and post-approval marketing studies. The preceding sentence shall not be construed in derogation
of QPharma’s obligations pursuant to Section 9.2 herein.

 

    13

    

    

 

7.7           Capital
Equipment; Process Development and Validation. QPharma shall develop and implement a plan for the acquisition and installation
of certain required capital equipment, and for the validation of the manufacturing process for the Product at the facilities where
it is to be Processed, pursuant to a written plan to be agreed to by the Parties within sixty (60) days following the Effective
Date (the “Validation Plan”). The Validation Plan shall set forth the obligations of QPharma with regard to
equipment procurement and installation, process and facility validation activities, and the headcount, the budget (on a not-to-exceed
basis) and the timeline for the accomplishment of such activities. Validation costs and expenses, including stability testing,
will not exceed $[***]. Capital equipment procurement and installation costs and expenses will not exceed $[***]. The elements
of the foregoing costs and expenses shall be set forth in the Validation Plan.

 

7.8           Manufacturing
and Cost Improvement. Promptly following execution and delivery of this Agreement, the parties shall confer, as advisable,
to formulate and put in place a plan for continuous improvement in manufacturing after considering appropriate means by which
to increase efficiency, yield and process improvement with a view toward lowing the Unit Pricing for Product.

 

ARTICLE
8

CHANGES
TO SPECIFICATIONS

 

8.1           All
Specifications and any changes thereto agreed to by the parties from time to time shall be in writing, dated and signed by the
parties. No change in the Specifications shall be implemented by QPharma, whether requested by TXMD or requested or required by
any Regulatory Authority, until the parties have agreed in writing to such change, the implementation date of such change, and
any increase or decrease in costs, expenses or fees associated with such change (including any change to Unit Pricing). QPharma
shall respond promptly to any request made by TXMD for a change in the Specifications, and both parties shall use commercially
reasonable, good faith efforts to agree to the terms of such change in a timely manner. As soon as possible after a request is
made for any change in Specifications, QPharma shall notify TXMD of the costs associated with such change and shall provide such
supporting documentation as TXMD may reasonably require. TXMD shall pay all costs associated with such agreed upon changes. If
there is a conflict between the terms of this Agreement and the terms of the Specifications, this Agreement shall control. QPharma
reserves the right to postpone effecting changes to the Specifications until such time as the parties agree to and execute the
required written amendment.

 

ARTICLE
9

RECORDS;
REGULATORY MATTERS

 

9.1           Recordkeeping.
QPharma shall maintain complete and accurate Batch, laboratory data, reports and other technical records relating to Processing
in accordance with QPharma standard operating procedures. Such information shall be maintained for a period of at least [***]
([***]) years from the relevant finished Product expiration date or longer if required under Applicable Laws or the Quality Agreement.
QPharma will retain samples required by cGMP and such samples shall be stored at the Facility pursuant to QPharma’s standard
operating procedures. Prior to the destruction of any such Product specific items, QPharma shall notify TXMD of the impending
destruction and provide TXMD a reasonable opportunity to receive any or all such items.

 

    14

    

    

 

9.2          Regulatory
Compliance. QPharma shall obtain and maintain, at its cost and expense, all permits and licenses with respect to general Facility
operations required by any Regulatory Authority in the jurisdiction where QPharma Processes Product and by any Regulatory Authority
in the Territory. QPharma acknowledges that the Product is a hormonal product and as such is subject to specialized regulations
relating to its manufacture. QPharma’s Facility presently complies with such regulations and QPharma shall maintain the
Facility’s compliance with such regulations. TXMD shall obtain and maintain, at its cost and expense, all other Regulatory
Approvals, authorizations and certificates, including those necessary for QPharma to commence Processing for the Territory. Upon
reasonable written request, TXMD shall provide QPharma with a copy of applicable Regulatory Approvals required to distribute,
market and sell Product in the Territory. If TXMD is unable to provide such information, QPharma shall have no obligation to deliver
Product to TXMD, notwithstanding anything to the contrary in this Agreement. During the Term, QPharma will assist TXMD with all
regulatory matters relating to Processing and review the Common Technical Document pertaining to the Product and make such corrections
as are necessary to accurately reflect the Product, in each case at TXMD’s request and reasonable expense; provided, however,
QPharma shall review and correct such documents as they relate to QPharma activities at no charge to TXMD. The parties intend
and commit to cooperate to allow each party to satisfy its obligations under Applicable Laws relating to Processing under this
Agreement.

 

9.3          Regulatory
Communications.

 

A.             Each
party may communicate with any governmental agency, including, but not limited to, governmental agencies responsible for granting
regulatory approval for the Products, regarding such Products if in the opinion of that party’s counsel, such communication
is necessary to comply with the terms of this Agreement or the requirements of any Applicable Law; provided, however, that unless
in the reasonable opinion of its counsel there is a legal prohibition against doing so, such party will permit the other party
to review and take part in any communications with the applicable agency, and to receive copies of all such communications from
that agency.

 

B.             QPharma
will notify TXMD promptly if QPharma receives any warning letters from or on behalf of a governmental agency directly related
to the Product or systems utilized in Processing the Product including, without limitation, any Form FDA-483. QPharma will provide
TXMD copies of any written communication from a governmental agency relating to a TXMD Product within [***] ([***]) Swedish business
days of its receipt.

 

C.             QPharma
will promptly notify TXMD upon receipt of a notice from a Regulatory Authority for an inspection of any Facility where the Processing
is being performed due to an issue related to the Product or a system used in the performance of such services, or, in the event
of an unannounced inspection, QPharma will provide such prior notice as is possible and permissible. If not prohibited by the
Regulatory Authority, TXMD will have the right to be present at the Facility and participate in and any wrap-up meeting with such
Regulatory Authority as it applies to the Product. If QPharma receives any request by a Regulatory Authority with respect to the
Product, including, but not limited to, a notice of deficiency or FDA-483 that requires a written response regarding TXMD-supplied
Materials, project, or protocol, QPharma will provide a copy to TXMD of the deficiency notice within [***] ([***]) [***] of QPharma’s
receipt of the notice. QPharma will provide TXMD a draft of the response prior to the response being submitted to the Regulatory
Authority so as to provide TXMD with reasonable time to review and comment on the response, which comments QPharma, in good faith,
will consider incorporating into the response.

 

    15

    

    

 

9.4           Governmental
Inspections and Requests. QPharma shall promptly advise TXMD if an authorized agent of any Regulatory Authority notifies QPharma
that it intends to or does visit a Facility or any other site for the purpose of reviewing the Processing or testing. Upon request,
QPharma shall provide TXMD with a copy of any report issued by such Regulatory Authority received by QPharma following such visit,
redacted as appropriate to protect any confidential information of QPharma and QPharma’s other customers. TXMD acknowledges
that it may not direct the manner in which QPharma fulfills its obligations to permit inspection by and to communicate with Regulatory
Authorities, but such acknowledgement shall not be construed to vitiate QPharma’s obligations to TXMD pursuant to this Agreement.
TXMD will not be required to pay costs to mitigate any deficiencies cited in a Form 483 or QPharma’s Facility deficiencies.

 

9.5           TXMD
Facility Audits. During the Term, TXMD’s Representatives shall be granted access upon at least [***] ([***]) business
days’ prior notice, at reasonable times during regular business hours, to (A) the portion of the Facility where QPharma
performs Processing, (B) relevant personnel involved in Processing and (C) Processing records described in Section 9.2, in each
case solely for the purpose of verifying that QPharma is Processing in accordance with cGMPs, Applicable Laws, the Specifications
and the Product master Batch records. TXMD may not conduct an audit under this Section more than once during any [***]-month period;
provided, that additional unlimited inspections may be conducted by or on behalf of TXMD as deemed appropriate by TXMD in the
event there is a material quality or compliance issue concerning Product or its Processing or to measure remediation following
an audit by either TXMD or a Regulatory Authority that resulted in a finding of deficiency. TXMD’s Quality Assurance Manager
will arrange TXMD audits with QPharma Quality Management. Audits shall be designed to minimize disruption of operations at the
Facility. TXMD’s Representatives who are not employees of TXMD shall be required to sign QPharma’s standard visitor
confidentiality agreement prior to being allowed access to the Facility. Such Representatives shall comply with the Facility’s
rules and regulations which are made known in advance to TXMD. TXMD shall indemnify and hold harmless QPharma for any action or
activity of such Representatives while on QPharma’s premises. QPharma shall not be required to accommodate any activity
that would violate GMP or Swedish law.

 

9.6           Recall.
If a Regulatory Authority orders or requires the recall of any Product supplied hereunder or if either QPharma or TXMD believes
a recall, field alert, Product withdrawal or field correction (“Recall”) may be necessary with respect to any
Product supplied under this Agreement, the party receiving the notice from the Regulatory Authority or that holds such belief
shall promptly notify the other party in writing. With respect to any Recall, QPharma shall provide all necessary cooperation
and assistance to TXMD. TXMD shall provide QPharma with an advance copy of any proposed submission to a Regulatory Authority in
respect of any Recall, and shall consider in good faith any comments from QPharma. The cost of any Recall shall be borne by TXMD,
and TXMD shall reimburse QPharma for expenses incurred in connection with any Recall, in each case except to the extent such Recall
is caused by QPharma’s breach of its Processing obligations under this Agreement or QPharma’s violation of Applicable
Laws, then such cost shall be borne by QPharma in proportion to QPharma’s contribution to the cause of the Recall, limited
to an amount equal to the aggregate price for all Product subject to Recall plus the price for all Product sold to TXMD during
the [***] ([***]) [***] period prior to Recall. For purposes hereof, such QPharma cost shall be limited to reasonable, actual
and documented administrative costs incurred by TXMD for such Recall and if applicable, replacement of the Product subject to
Recall both in accordance with Article 5.

 

    16

    

    

 

9.7           Quality
Agreement. The parties shall negotiate in good faith and enter into a quality agreement on QPharma’s standard template
or such other template agreed to by the parties (the “Quality Agreement”). If the parties have not entered
into a Quality Agreement by the first to occur of (i) [***] ([***]) days following the date execution by the last party signing
this Agreement or (ii) commencement of manufacturing of Product for human use, TXMD shall be entitled to terminate this Agreement
on [***] ([***]) days’ written notice to QPharma, without cost or expense; provided, however, TXMD shall reimburse QPharma
for any (i) equipment acquired by QPharma upon written authorization of TXMD and (ii) Raw Materials procured upon written authorization
by TXMD, which unused Raw Materials, at the election of TXMD, and such equipment shall become the property of TXMD upon payment
pursuant to this Section. The Quality Agreement shall in no way determine liability or financial responsibility of the parties
for the responsibilities set forth therein. In the event of a conflict between any of the provisions of this Agreement and the
Quality Agreement with respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement
shall govern. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect
to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement
shall govern.

 

9.8           Audit
of Suppliers. QPharma shall be responsible for the audit of suppliers in accordance with its standard auditing plans and practices.
TXMD hereby agrees to conduct audits on behalf of QPharma of suppliers with locations in the United States, currently only [***],
and of certain contract laboratories to be agreed to by QPharma and TXMD. QPharma will reimburse to TXMD its out-of-pocket costs
in conducting such audits. TXMD is responsible for API audits. QPharma can audit other relevant suppliers, including [***] and
[***].

 

ARTICLE
10

CONFIDENTIALITY
AND NON-USE

 

10.1         Definition.
As used in this Agreement, the term “Confidential Information” includes all information furnished by or on
behalf of QPharma or TXMD, their respective Affiliates or any of its or their respective Representatives (the “Discloser”),
to the other party (the “Recipient”), its Affiliates or any of its or their respective Representatives, whether
furnished before, on or after the date of this Agreement, and furnished in any form, including written, verbal, visual, electronic
or in any other media or manner and information acquired by observation or otherwise during any site visit at the other party’s
facility. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and
any other intellectual property (whether or not patented), analyses, data, regulatory submission Information, compilations, business
or technical information, strategies, or plan, samples, and other materials prepared or possessed by either party, their respective
Affiliates, or any of its or their respective Representatives, containing or based in whole or in part on any information furnished
by the Discloser, its Affiliates or any of its or their respective Representatives. Confidential Information also includes the
existence of this Agreement and its terms. The manufacturing process parameters which are being provided to QPharma from TXMD,
the Specifications and data resulting from performance of this Agreement by QPharma shall be considered TXMD’s Confidential
Information. Items and information for which ownership has been allocated to TXMD under the Development Agreement shall be deemed
to be the Confidential Information of TXMD under this Agreement.

 

    17

    

    

 

10.2         Exclusions.
Notwithstanding Section 10.1, Confidential Information does not include information that (A) is or becomes generally available
to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, (B)
is already known by the Recipient at the time of disclosure as evidenced by the Recipient’s written records created in the
ordinary course of business, (C) becomes available to the Recipient on a non-confidential basis from a source that is entitled
to disclose it on a non-confidential basis or (D) was or is independently developed by or for the Recipient without reference
to the Confidential Information of the Discloser as evidenced by the Recipient’s contemporaneously created written records
(E) is required to be disclosed by a court or judicial or governmental authority of competent jurisdiction, and in such event,
only after the party required to disclose the other party’s Confidential Information provides prompt written notice to that
party so as to enable that party to resist any such required disclosure and/or to obtain suitable protection regarding such required
disclosure as is described in provision 10.4 below

 

10.3         Mutual
Obligation. The Recipient agrees that it will not use the Discloser’s Confidential Information except in connection
with the performance of its obligations or the exercise of its rights under this Agreement, and will not disclose, without the
prior written consent of the Discloser, Confidential Information of the Discloser to any third party, except that the Recipient
may disclose the Discloser’s Confidential Information to any of its Affiliates and its or their respective Representatives
and subcontractors for which consent has been given pursuant to Section 6.3 and who have obligations of confidentiality and non-use
at least as rigorous as those terms herein, in each case, that (A) need to know such Confidential Information for the purpose
of performing under this Agreement, (B) are advised of the contents of this Article and (C) are bound to the Recipient by obligations
of confidentiality at least as restrictive as the terms of this Article. Each party shall be responsible for any breach of this
Article by its Affiliates or any of its or their respective Representatives or any person receiving Confidential Information directly
or indirectly from or through the Recipient. The Recipient also may disclose any information to The Population Council, as may
be required by any written contract now in existence.

 

10.4         Permitted
Disclosure. The Recipient may disclose the Discloser’s Confidential Information to the extent required by law or regulation;
provided, that prior to making any such legally required disclosure, the Recipient shall give the Discloser as much prior
notice of the requirement for and contents of such disclosure as is practicable under the circumstances. Any such disclosure,
however, shall not relieve the Recipient of its obligations contained herein.

 

10.5         No
Implied License. Except as expressly set forth in Section 10.1, the Recipient will obtain no right of any kind or license
under any Confidential Information of the Discloser, including any patent application or patent, by reason of this Agreement.
All Confidential Information will remain the sole property of the Discloser, subject to Article 11.

 

10.6         Return
of Confidential Information. Upon expiration or termination of this Agreement, the Recipient will (and will cause its Affiliates
and its and their respective Representatives to) cease its use and, upon written request, within thirty (30) days either return
or destroy (and certify as to such destruction) all Confidential Information of the Discloser, including any copies thereof, except
for a single copy which may be retained for the sole purpose of ensuring compliance with its continuing obligations under this
Agreement.

 

    18

    

    

 

10.7        Survival.
The obligations of this Article will terminate with respect to items of Confidential Information upon the entry thereof into general
knowledge in the public domain, other than due to breach of this Agreement by the Recipient thereof or by a person receiving such
Confidential Information from or through the Recipient, but in no event earlier than [***] ([***]) years from the expiration or
earlier termination of this Agreement.

 

10.8        Reverse
Engineering. Unless otherwise consented to by the Discloser in writing or provided for in a separate agreement between the
parties, the Recipient will not analyze for chemical composition any samples or materials that are the Confidential Information
of Discloser, nor to allow or cause any such samples or materials that are the Confidential Information of Discloser to be released
to third parties for analysis; provided, however, (i) this Section 10.8 shall not be construed to prevent TXMD from testing Product
or items related to Product itself or through third parties, as it sees fit in its sole and absolute discretion; and (ii) this
Section 10.8 shall not be construed to prevent QPharma from analyzing for chemical composition samples or materials that are commercially
available.

 

ARTICLE
11
INTELLECTUAL PROPERTY

 

11.1        The
parties hereby acknowledge that it is neither their intention nor the purpose of this Agreement to engage in inventive steps in
the conception, reduction to practice or development of intellectual property. Nevertheless, in the event, and to the extent,
that intellectual property is conceived, reduced to practice, developed or otherwise created by or on behalf of either or both
of the parties in connection with this Agreement, the ownership of such intellectual property, as between the parties, shall be
with TXMD with respect to such intellectual property that relates to the Product and its Processing. Otherwise ownership shall
be with QPharma.

 

11.2        Transfer.
Following notice given by TXMD to QPharma, QPharma will provide reasonable assistance to effect the timely and orderly transfer
of the Process Know-How, and pertinent books and records (or copies thereof, as the case may be) pursuant to the Process Know-How
Transfer Plan to TXMD pursuant to this Section 11.2 and the Process Know-How Transfer Plan whether to establish a second source
during the term of this Agreement or at or about the time of termination or expiration of this Agreement. QPharma shall only be
obligated to use its commercially reasonable efforts in the implementation of the Process Know-How Transfer Plan. QPharma will
be reimbursed at a reasonable rate for the time of its personnel for such technology transfer.

 

11.3         Books
and Records. Where any document, or books and records contain Process Know-How together with other information of QPharma,
its Affiliates or their respective subcontractors, or other QPharma customers, QPharma shall only be required to provide to TXMD
a copy of that portion of that document or books and records that discloses the Process Know-How that pertains to the Product.
When transferred to TXMD, such copies will be the property of TXMD. QPharma may retain the original books and records and any
documents required by Applicable Laws to be retained by QPharma, which disclose the Process Know-How. After completion of performance
of the Process Know-How Transfer Plan, before destroying any documents, or books and records which contain material disclosures
of Process Know-How that have not been previously been provided to TXMD (whether in the same form or some other form), QPharma
will notify TXMD of such intended destruction and provide TXMD with [***] ([***]) days to notify QPharma in writing whether TXMD
wishes to obtain the same to the extent it is entitled to under this Agreement, in which case QPharma will deliver the requested
document or books and records (or copies of all or a portion thereof, as the case may be) to TXMD at TXMD’s sole cost and
expense.

 

    19 

     

    
 

11.4       TXMD
Marks. QPharma will not use TXMD’s Marks without prior written authorization from TXMD. The Marks are, and will remain,
TXMD’s sole and exclusive property, and QPharma has not acquired, and will not acquire (by operation of law, this Agreement,
or otherwise), any right, title, or interest in any of TXMD’s Marks other than as explicitly provided in writing by TXMD.
Any and all goodwill and rights that arise under trademark and copyright law, and all other intellectual property rights that
arise in favor of TXMD’s Marks as a result of this Agreement or otherwise, will inure to the sole and exclusive benefit
of TXMD. Subject to the next sentence, during the Term of this Agreement, QPharma will not attack, dispute, or challenge TXMD’s
right, title, and interest in and to TXMD’s Marks or assist others in so doing. QPharma reserves the right to attack, dispute,
or challenge TXMD’s right, title, and interest in and/or to TXMD’s Marks or assist others in so doing, if QPharma
believes in good faith that TXMD’s Mark infringes a Mark owned by or licensed to QPharma or one of its Affiliates. 

 

ARTICLE
12
REPRESENTATIONS AND WARRANTIES AND COMPLIANCE

 

12.1       QPharma. QPharma represents, warrants and undertakes to TXMD that:

 

A.      at
the time of delivery by QPharma as provided in Section 6.1, Product shall have been Processed in accordance with this Agreement
and with Applicable Laws and in conformance with the Specifications and shall not be adulterated, misbranded or mislabeled within
the meaning of Applicable Laws; provided, that QPharma shall not be liable for defects attributable to TXMD-supplied Materials
(including artwork, advertising and labeling); 

 

B.      all
personnel, employees, and agents of QPharma and its Affiliates and their respective subcontractors who perform services, are and
will continue to be qualified and to have sufficient technical expertise to perform QPharma’s obligations under this Agreement;

 

C.      QPharma
has the full power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described
in this Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon QPharma;

 

D.      QPharma
is not now, nor will it be, a party to any agreement, whether with The Population Council or others, which would prevent QPharma
from fulfilling its obligations under this Agreement, and that during the Term of this Agreement will not enter into any agreement
with any other party that would in any way prevent QPharma from performing its obligations under this Agreement;

 

    20 

     

    

E.      QPharma’s
Facility complies with and QPharma will maintain its compliance with the regulations for the manufacture of hormonal products;

 

F.      QPharma
will maintain all records and reports as required under this Agreement, and as required to comply with Applicable Laws;

 

G.      QPharma
will not in the performance of its obligations under this Agreement use those services prohibited to be provided by any person
debarred or suspended (or subject to debarment or suspension) under 21 U.S.C. §335(a) or (b) or otherwise disqualified by
Applicable Law; 

 

H.      (i)
QPharma is not nor has it ever been, and (ii) QPharma has not used, and will not use, the services of any person excluded, debarred,
suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or non-procurement
programs, and has not used, and will not use, those services prohibited to be provided by any person listed on the HHS/OIG List
of Excluded Individuals/Entities (http://www.oig.hhs.gov), the GSA’s List of Parties Excluded from Federal Programs
(http://www.epls.gov), or the FDA Debarment List (http://www.fda.gov/ora/compliance_ref/debar/default.htm), as amended
or replaced from time to time, in connection with any of the services performed under this Agreement. QPharma further certifies
that it, and, to its knowledge, any other person or entity used by QPharma in performing any of the services under this Agreement,
has not been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a-7(a). QPharma agrees to notify
TXMD promptly in the event QPharma, or any person used by QPharma in connection with this Agreement, ever becomes excluded, debarred,
suspended, or, otherwise to its knowledge, ineligible to participate in Federal health care programs or in Federal procurement
or non-procurement programs. This certification applies to QPharma and its respective officers, agents, and employees as well
as subcontractors performing on behalf of QPharma under this Agreement;

 

I.      QPharma
has all necessary authority to use the QPharma technology utilized with the Product and as contemplated by this Agreement; there
are no patents owned by others related to the QPharma IP utilized with the Product that would be infringed or misused by QPharma’s
performance of the Agreement; and, to its knowledge, no trade secrets or other proprietary rights of others related to the QPharma
IP utilized with the Product that would be infringed or misused by QPharma’s performance of this Agreement; 

 

J.      QPharma
will not release any Batch of Product if the required certificates of conformance indicate that Product does not comply with the
Specifications; and

 

K.      no
transactions or dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the
target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the
United States. 

 

12.2       TXMD.
TXMD represents, warrants and undertakes to QPharma that:

 

A.      all
TXMD-supplied Materials shall have been produced in accordance with Applicable Laws, shall comply with all applicable specifications,
including the Specifications, shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws, and shall
have been provided in accordance with the terms and conditions of this Agreement; 

 

    21 

     

    
 

B.      the
content of all artwork provided to QPharma shall comply with all Applicable Laws; 

 

C.      all
Product delivered to TXMD by QPharma shall be held, used and disposed of by or on behalf of the TXMD in accordance with all Applicable
Laws, and TXMD will otherwise comply with all laws, rules, regulations and guidelines applicable to TXMD’s performance under
this Agreement; 

 

D.      TXMD
will not release any Batch of Product if the required certificates of conformance indicate that Product does not comply with the
Specifications or if TXMD does not hold all necessary Regulatory Approvals to market and sell the Product; 

 

E.      TXMD
has all necessary authority to use and to permit QPharma to use pursuant to this Agreement all intellectual property related to
Product or TXMD-supplied Materials (including artwork), and the Processing by QPharma of the foregoing, including any copyrights,
trademarks, trade secrets, patents, inventions and developments; to TXMD’s knowledge there are no patents owned by others
related to the TXMD IP utilized with the Product that would be infringed or misused by TXMD’s performance of the Agreement;
and, to its knowledge, no trade secrets or other proprietary rights of others related to the TXMD IP utilized with the Product
that would be infringed or misused by TXMD’s performance of this Agreement; 

 

F.      To
TXMD’s knowledge the services to be performed by QPharma under this Agreement will not violate or infringe upon any trademark,
tradename, copyright, patent, trade secret, or other intellectual property or other right held by any person or entity; provided
that TXMD makes no representation with respect to the QPharma IP; 

 

G.      TXMD
has the full power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described
in this Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon TXMD; and

 

H.      no
transactions or dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the
target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the
United States. 

 

12.3        Limitations.
THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY
EACH PARTY TO THE OTHER PARTY, AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER,
INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE INCLUDING, WITHOUT LIMITATION,
ANY REPRESENTATION OR WARRANTY BY TXMD WITH REGARD TO THE TXMD EQUIPMENT, WHICH IS PROVIDED “AS IS.”

 

12.4        Compliance
with Anti-Corruption Laws.

 

Each
Party agrees that, in the performance of its obligations under this Agreement, it will not: (i) provide or promise to provide,
directly or indirectly, any unlawful contribution, gift, entertainment, or other unlawful payment to any foreign or domestic government
employee relating to political activity; (ii) take any action, directly or indirectly, that violates Foreign Corrupt Practices
Act (“FCPA”), or any other applicable anti-corruption law of any foreign jurisdiction, including, without limitation,
“use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay, or authorization of the payment of any money, or offer, gift, promise to give, or authorization of the giving
of anything of value” to any “foreign official” (as is defined in the FCPA), any foreign political party or
official thereof, or any candidate for foreign political office, to influence their acts or decisions in their official capacity,
to induce them to do or omit from doing any act in violation of their lawful duty, or to secure any improper advantage in order
to assist in obtaining business, or retaining business, or directing business to any person; and (iii) make or propose to make
any bribe, payoff, influence payment, kickback, unlawful rebate, or other similar unlawful payment of any nature, including to
healthcare providers or those employed by any governmental institutions.

 

    22 

     

    
 

12.5       Covenant
of QPharma. QPharma hereby covenants and agrees that it shall neither directly or indirectly, on behalf of itself or a third
party, engage in or assist a third party, in developing, manufacturing or commercializing a generic product of the Product in
the Territory during the Term of this Agreement, and during the [***] ([***]) month period thereafter. [***].

 

ARTICLE
13
INDEMNIFICATION

 

13.1       Indemnification
by QPharma. QPharma shall indemnify, defend and hold harmless TXMD, its Affiliates, and their respective shareholders, directors,
officers and employees (“TXMD Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities,
damages, costs and expenses (including reasonable attorneys’ fees and reasonable investigative costs) in connection with
any suit, demand or action brought by any third party (“Losses”) directly or indirectly arising out of or resulting
from (a) any breach of its representations, warranties or obligations set forth in this Agreement; (b) any negligence or willful
misconduct by QPharma, its Affiliates, subcontractors, employees or agents; (c) any misrepresentation made by QPharma in this
Agreement; (d) a violation of, or non-compliance with any Applicable Law by QPharma, its Affiliates, subcontractors, employees
or agents in the performance of this Agreement; (e) the infringement or alleged infringement of any trade secrets, copyrights,
trademarks, trade names, or other proprietary or contractual rights of any third party arising from QPharma’s performance
of services under this Agreement (except to the extent arising from the making or using of TXMD-supplied Materials) or (f) the
use of the TXMD Equipment on behalf of any third party, and the storage, handling and use of any items manufactured with the use
of the TXMD Equipment, in each case of clauses (a) through (e) above, except to the extent that TXMD is obligated to indemnify
any of the QPharma Indemnitees pursuant to Section 13.2 for such events.

 

13.2       Indemnification
by TXMD. TXMD shall indemnify, defend and hold harmless QPharma, its Affiliates, and their respective shareholders, directors,
officers and employees (“QPharma Indemnitees”) from and against any and all Losses directly or indirectly arising
out of or resulting from (a) any promotion, distribution, sale or use of or exposure to the Product or TXMD-supplied Materials,
or APIs, other than claims by QPharma employees and contractors arising from Processing under this Agreement; (b) any negligence
or willful misconduct of TXMD, its Affiliates, subcontractors, employees or agents, (c) any breach of TXMD’s representations,
warranties or obligations set forth in this Agreement; (d) the content of TXMD’s instructions to the extent they are followed
by QPharma and violate Applicable Laws; (e) the conduct of any clinical trials by or on behalf of TXMD utilizing Product or APIs;
(f) any actual or alleged infringement or violation of any third party patent, trade secret, copyright, trademark or other proprietary
right by the use, as authorized, of intellectual property or other information provided by TXMD to QPharma, including TXMD-supplied
Material; in each case of clauses (a) through (f) above, except to the extent that QPharma is obligated to indemnify any of the
TXMD Indemnitees pursuant to Section 13.1 for such events. 

 

    23 

     

    
 

13.3       Indemnification
Procedures. All indemnification obligations in this Agreement are conditioned upon the indemnified party (a) promptly notifying
the indemnifying party of any claim or liability of which the indemnified party becomes aware (including a copy of any related
complaint, summons, notice or other instrument); provided, that failure to provide such notice within a reasonable period of time
shall not relieve the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced
by such failure, (b) allowing the indemnifying party to conduct and control the defense of any such claim or liability and any
related settlement negotiations (at the indemnifying party’s expense), (C) cooperating with the indemnifying party in the
defense of any such claim or liability and any related settlement negotiations (at the indemnifying party’s expense) and
(D) not compromising or settling any claim or liability without prior written consent of the indemnifying party.

 

ARTICLE
14
LIMITATIONS OF LIABILITY

 

14.1       NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOSS OF REVENUES,
PROFITS OR DATA ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES.

 

ARTICLE
15
INSURANCE

 

For
so long as each Party has any indemnity obligations hereunder to the other Party, each Party shall obtain and maintain such type
and amounts of liability insurance as are normal and customary for the activities contemplated by this Agreement. Each Party shall
upon request provide the other Party with written proof of insurance. Notwithstanding the foregoing, QPharma hereby represents
and warrants to TXMD that it has and shall maintain at all times during the term of this Agreement product liability insurance,
professional negligence insurance and general commercial liability insurance in a minimum in aggregate of [***] Euros (€[***]).
QPharma shall name TXMD as an additional named insured under such policies.

 

    24 

     

    
 

ARTICLE
16
TERM AND TERMINATION

 

16.1        Term.
The term of this Agreement shall commence as of the Effective Date and shall expire at the end of the Initial Term; provided,
however, TXMD shall have the right to renew the Agreement thereafter for successive one-year terms upon giving at least [***]
([***]) days’ written notice of such renewal prior to the expiration of the Initial Term or any annual renewal thereafter.

 

16.2        Termination.
This Agreement may be terminated Immediately upon written notice without further action:

 

A.      By
either Party if the other Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for
or consents to the appointment of a receiver, administrative receiver, trustee or administrator, or makes an assignment for the
benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order
is not discharged within thirty (30) days, or takes any equivalent or similar action in consequence of debt in any jurisdiction;
or

 

B.      By
TXMD upon [***] ([***]) days prior written notice to QPharma in the event TXMD ceases pursuit of Regulatory Approval for, or to
offer for sale or to sell, Product, due to material regulatory, patient health, or intellectual property issues. 

 

C.      By
either Party due to an uncured breach of this Agreement following [***] ([***]) days’ written notice, the elements of such
breach being described in such notice in reasonable detail.

 

D.      By
TXMD for convenience upon [***] ([***]) months’ written notice, or by QPharma after the first anniversary of this Agreement
upon [***] ([***]) months’ written notice due to the failure of QPharma to produce Product at a profit based upon the then
existing supply projections by TXMD or for other demonstrated economic hardship. Upon notice from QPharma of the exercise of its
rights under this Section 16.2(D) to terminate the Agreement, TXMD shall have the right exercisable in the [***] ([***]) day period
following such notice to require QPharma to re-negotiate the price of Products in good faith for a period of up to [***] ([***])
days. The Parties shall not be obligated to reach agreement regarding a revised price of Products.

 

16.3        Effects
of Termination. Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued
to the benefit of either party prior to such expiration or termination. In the event of a termination of this Agreement:

 

A.      QPharma
shall promptly return to TXMD, at TXMD’s expense and direction, any remaining inventory of Product or TXMD-supplied Materials;
provided, that all outstanding invoices have been paid in full; 

 

B.      TXMD
shall pay QPharma all invoiced amounts outstanding hereunder, plus, upon receipt of invoice therefor, for any (i) Product that
has been shipped pursuant to Purchase Orders but not yet invoiced, (ii) Product Processed pursuant to Purchase Orders that has
been completed but not yet shipped, and (iii) except following a termination by TXMD pursuant to Section 16.2(A) or (B), all Product
in process of being Processed pursuant to Purchase Orders (or, alternatively, TXMD may instruct QPharma to complete such work
in process, and the resulting completed Product shall be governed by clause (ii)); and 

 

    25 

     

    
 

16.4       Except
as otherwise set forth in this Agreement, in the event that this Agreement is terminated for any reason other than by TXMD pursuant
to Section 16.2(A) or (B), TXMD shall pay QPharma for all costs and expenses incurred, and all non-cancellable commitments made,
in connection with QPharma’s performance of this Agreement, so long as such costs, expenses or commitments were made by
QPharma consistent with TXMD’s most recent ordering history, and have not otherwise been paid pursuant to Section 16.3(B).
At TXMD’s discretion, such transfer shall not be considered complete until such third party transferee has successfully
Processed and released for human use [***] ([***]) successive Batches of Product. If QPharma terminates this Agreement pursuant
to Section 16.2(D), it shall provide to TXMD reasonable person-hours as TXMD shall require, at QPharma’s then standard published
rates, to effectuate a transfer of Processing to a third party of TXMD’s choice. QPharma shall provide reasonable assistance,
as requested by TXMD, to identify third parties capable and willing to provide Processing of Product promptly.

 

16.5        Interruption
of Supply; Safety Stock.

 

A.      In
the event QPharma fails to timely deliver the quantities of Product ordered that comply with the requirements of this Agreement
on [***] ([***]) consecutive occasions or on any [***] ([***]) occasions during any [***] ([***]) [***] period, TXMD shall be
entitled to cause QPharma to conduct Process Know-How Transfer along with pertinent books and records to TXMD or its designee,
pursuant to the Process Know-How Transfer Plan in order to allow the Processing of Product by a third party for TXMD, its Affiliates
and their respective licensees. QPharma will be reimbursed at a reasonable rate for the time of its personnel for such technology
transfer.

 

B.      To
mitigate the risk of TXMD going out of stock, QPharma shall maintain such safety stocks of APIs, Raw Materials, Components and
Product as would be reasonably prudent in the combination drug-device product industry under relevant circumstances, particularly
in light of those APIs, Raw Materials and Components that are procured from single sources of supply. QPharma shall use reasonable
efforts to put in place a written risk mitigation plan with the consultation of TXMD to address such issues, and shall reasonably
endeavor to secure multiple sources of supply for all critical APIs, Raw Materials and Components (the “Risk Mitigation
Plan”).

 

16.6        Survival.
The rights and obligations of the parties shall continue under Articles 11 (Intellectual Property), 13 (Indemnification), 14 (Limitations
of Liability), 17 (Notice), 18 (Miscellaneous); under Articles 10 (Confidentiality and Non-Use) and 15 (Insurance), in each case
to the extent expressly stated therein; and under Sections 7.3 (Payment Terms), 7.5 (Taxes), 7.6 (TXMD and Third Party Expenses),
9.1 (Recordkeeping), 9.6 (Recall), 12.3 (Limitations on Warranties), 16.3 (Effect of Termination) and 16.4 (Survival), in each
case in accordance with their respective terms if applicable, notwithstanding expiration or termination of this Agreement. 

 

    26 

     

    
 

ARTICLE
17
NOTICE

 

All
notices and other communications hereunder shall be in writing and shall be deemed given: (A) when delivered personally or by
hand; (B) when received or refused, if sent by registered or certified mail (return receipt requested), postage prepaid; or (C)
when delivered, if sent by express courier service; in each case to the parties at the following addresses (or at such other address
for a party as shall be specified by like notice; provided, that notices of a change of address shall be effective only
upon receipt thereof): 

	 

	 

	To
TXMD:

	TherapeuticsMD,
Inc.

	 

	6800
Broken Sound Parkway NW, Third Floor

	 

	Boca
Raton, Florida 33487

	 

	Attn:
President

	 

	 

	With
a copy to:

	Legal
Department at the above address

	 

	 

	To
QPharma:

	QPharma
AB

	 

	Agneslundsvagen
27

	 

	Malmo,
Sweden

	 

	Attn:
Managing Director

 

ARTICLE
18
MISCELLANEOUS

 

18.1       Entire
Agreement; Amendments. This Agreement, the Quality Agreement, and the Validation Costs and Expenses; Capital Equipment Procurement
and Installation Costs and Expenses (referenced as Exhibit B to the Term Sheet) constitute the entire understanding between the
Parties, and supersede any contracts, agreements or understandings (oral or written) of the Parties, with respect to the subject
matter hereof including the Term Sheet, other than Exhibit B thereto. For the avoidance of doubt, this Agreement does not supersede
any existing generally applicable confidentiality agreement between the Parties as it relates to time periods prior to the date
hereof or to business dealings not covered by this Agreement. No term of this Agreement may be amended except upon written agreement
of both parties, unless otherwise expressly provided in this Agreement. 

 

18.2       Captions;
Certain Conventions. The captions in this Agreement are for convenience only and are not to be interpreted or construed as
a substantive part of this Agreement. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires,
(A) words of any gender include each other gender, (B) words such as “herein”, “hereof”, and “hereunder”
refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (C) words using the
singular shall include the plural, and vice versa, (D) the words “include(s)” and “including” shall be
deemed to be followed by the phrase “but not limited to”, “without limitation” or words of similar import,
(E) the word “or” shall be deemed to include the word “and” (e.g., “and/or”) and (F) references
to “Article,” “Section,” “subsection,” “clause” or other subdivision, or to an
Attachment or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement.
This Agreement shall be construed as if it were drafted jointly by the parties.

 

    27 

     

    
 

18.3       Further
Assurances. The parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental
acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 

18.4       No
Waiver. Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more instances
will not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure.

 

18.5       Severability.
If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining
terms of this Agreement will continue in full force and effect.

 

18.6       Independent
Contractors. The relationship of the parties is that of independent contractors, and neither party will incur any debts or
make any commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement
is intended to create or will be construed as creating between the parties the relationship of joint ventures, co-partners, employer/employee
or principal and agent. Neither party shall have any responsibility for the hiring, termination or compensation of the other party’s
employees or contractors or for any employee benefits of any such employee or contractor.

 

18.7       Successors
and Assigns. This Agreement will be binding upon and inure to the benefit of the parties, their successors and permitted assigns.
Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that
either party may, without the other party’s consent (but subject to prior written notice), assign this Agreement in its
entirety to an Affiliate or to a successor to substantially all of the business or assets of the assigning party or the assigning
party’s business unit responsible for performance under this Agreement.

 

18.8       No
Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the
parties named herein and their respective successors and permitted assigns.

 

18.9       Governing
Law. This Agreement shall be governed by and construed under the laws of England and Wales, excluding its conflicts of law
provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.

 

18.10     Dispute
Resolution. Any dispute that arises between the parties in connection with this Agreement shall first be presented to the
senior executives of the Parties for consideration and resolution. If such executives cannot reach a resolution of the dispute
within a reasonable time, then the parties may seek remedies in a court of law. 

 

18.11     Publicity.
Neither party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated
hereby without the other party’s express prior written consent, except as required under Applicable Laws, by any governmental
agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the party
required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the
other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or
making the public disclosure.

 

    28 

     

    
 

18.12     Right
to Dispose and Settle. If QPharma requests in writing from TXMD direction with respect to disposal of any inventories of Product,
TXMD-supplied Materials, equipment, samples or other items belonging to TXMD and is unable to obtain a response from TXMD within
a reasonable time period after making reasonable efforts to do so, QPharma shall be entitled in its sole discretion to (A) dispose
of all such items and (B) set-off any and all amounts due to QPharma or any of its Affiliates from TXMD against any credits TXMD
may hold with QPharma or any of its Affiliates.

 

18.13     Force
Majeure. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this
Agreement be terminable or cancelable by reason of, any delay or default in such party’s performance hereunder if such default
or delay is caused by events beyond such party’s reasonable control, including but not limited to acts of God, law or regulation
or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction of production
facilities or materials by earthquake, fire, flood or weather, labor disturbances, epidemic or failure of suppliers, vendors,
public utilities or common carriers; provided, that the party seeking relief under this Section shall immediately notify
the other party of such cause(s) beyond such party’s reasonable control. The party that may invoke this Section shall use
commercially reasonable efforts to reinstate its ongoing obligations to the other party as soon as practicable. If the cause(s)
shall continue unabated for three (3) consecutive months, then both parties shall meet to discuss and negotiate in good faith
what modifications to this Agreement should result from such cause(s).

 

18.14     Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall
constitute an original.

 

[Signature
page follows]

 

    29 

     

    
 

IN
WITNESS WHEREOF, the parties have caused their respective duly authorized Representatives to execute this Agreement effective
as of the date first written above. 

	 

	 

	 

	 

	 

	 

	 

	 

	 

	QPHARMA
PHARMA AB

	 

	THERAPEUTICSMD,
INC.

	 

	 

	 

	By:

	/s/
David Segerberg

	 

	By:

	/s/
Dan Cartwright

	 

	 

	 

	 

	 

	Name:

	David
Segerberg

	 

	Name:

	Dan
Cartwright

	 

	 

	 

	 

	 

	Title:

	Managing
Director

	 

	Title:

	CFO

 

     

     

    
 

ATTACHMENT
A

 

SPECIFICATIONS

 

     

     

    
 

ATTACHMENT
B

 

TXMD
EQUIPMENT (as of 12/18/18)

 

Purchased
Assets
Equipment used for production and analysis of NES/EE CVR

 

	Description
(swe)

	Description
(eng)

	Equipment
No

	Process
step

	QPharma
Building

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	 

	 

	 

	 

	 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	 

	 

	 

	 

	 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	 

	 

	 

	 

	 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	 

	 

	 

	 

	 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	 

	 

	 

	 

	 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

 

     

     

    

 

ATTACHMENT
C

 

TXMD-SUPPLIED
MATERIALS (as of 12/18/18)

 

[***]

 

     

     

    

ATTACHMENT
D

 

UNIT
PRICING

 

During
the Initial Pricing Period, QPharma shall sell Product in final dosage form, packaged for end user use, to TXMD at the prices
set forth below. [***]

 

[***]

 

	Purchase
Per Contract Year

	 

	 

	Prices
Not to Exceed (low yield)

	 

	 

	 

	 

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	More
than [***] units of Product

	 

	 

	$[***]
per unit

	 

	 

	 

	 

	Purchase
Per Contract Year

	 

	Prices
Not to Exceed (anticipated yield)

	 

	 

	 

	 

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	[***]
– [***] units of Product

	 

	 

	$[***]
per unit

	More
than [***] units of Product

	 

	 

	To
be determined

 

The
foregoing prices include a recovery for depreciation expenses of Facility improvements made by QPharma. Recovery of these depreciation
expenses will end upon expiration of the depreciation recovery schedule. TXMD will purchase a minimum of [***] units of Product
per Contract Year.

 

The
foregoing prices include the purchase by, and payment for, both of the Product’s APIs by QPharma. If TXMD supplies one or
both of the Product’s APIs to QPharma at no cost, or QPharma procures one or both APIs and passes the cost through to TXMD,
the foregoing prices will be adjusted downward, as reasonably agreed to by QPharma and TXMD.

 

     

     

    

 

These
prices will be applied to cumulative purchased by TXMD together with its Affiliates and licensees, if any. The unit price for
which QPharma will sell Product to TXMD, its Affiliates and their licensees during the Initial Pricing Period will be as set forth
in the table above in accordance with the cumulative quantities ordered by and on behalf of such parties during each Contract
Year. Within [***] ([***]) days following (i) the end of each Contract Year or (ii) the expiration or termination of the Agreement,
as the case may be, QPharma shall determine the total quantity of Product ordered by or on behalf of TXMD, its Affiliates and
their respective licensees during the prior Contract Year (or portion of a Contract Year in the event of a termination) and issue
a credit memo or refund to TXMD, at its option, in such amount as may be necessary to true up amounts actually paid by TXMD with
the prices to which TXMD, its Affiliates and their respective licensees were entitled during such Contract Year based on their
actual cumulative orders.

 

TXMD
and QPharma will revisit this yield-based pricing scheme after the first commercial Batch of Product as defined in Section 7.1A.TherapeuticsMD, Inc. 10-Q

Exhibit 10.2

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

 

LEASE

 

BY AND BETWEEN

 

951 YAMATO ACQUISITION COMPANY, LLC

(“Landlord”)

 

and

 

TherapeuticsMD, Inc.

(“Tenant”)

     

     

    
 

TABLE OF CONTENTS

 

	
 

	
 

	
Page

	
1.

	
TERMS

	
1

	
2.

	
THE PREMISES

	
4

	
3.

	
TERM

	
5

	
4.

	
CONDITION OF THE PREMISES

	
5

	
5.

	
MONTHLY RENT

	
6

	
6.

	
TAXES

	
7

	
7.

	
OPERATING EXPENSES

	
8

	
8.

	
RECONCILIATION

	
10

	
9.

	
INSURANCE

	
12

	
10.

	
WAIVER OF SUBROGATION

	
13

	
11.

	
SECURITY DEPOSIT

	
14

	
12.

	
USE

	
14

	
13.

	
MAINTENANCE; SERVICES

	
15

	
14.

	
SUBLEASE; ASSIGNMENT

	
16

	
15.

	
INDEMNITY; NON-LIABILITY OF LANDLORD

	
18

	
16.

	
UTILITIES

	
19

	
17.

	
HOLDING OVER

	
20

	
18.

	
NO RENT DEDUCTION OR SET OFF

	
20

	
19.

	
CASUALTY

	
20

	
20.

	
SUBORDINATION; ESTOPPEL LETTERS

	
21

	
21.

	
ALTERATIONS; RESTORATION

	
22

	
22.

	
DEFAULT; REMEDIES

	
24

	
23.

	
LANDLORD’S DEFAULT

	
27

	
24.

	
NOTICES

	
27

	
25.

	
EMINENT DOMAIN

	
28

	
26.

	
QUIET ENJOYMENT

	
28

	
27.

	
RULES AND REGULATIONS

	
28

	
28.

	
ENVIRONMENTAL

	
29

	
29.

	
INTENTIONALLY OMITTED

	
29

 

i

 

 

 

	
30.

	
BROKERS

	
29

	
31.

	
MISCELLANEOUS

	
30

	
32.

	
SOUTH FLORIDA COMMUTER SERVICE PROGRAMS

	
31

	
33.

	
CITY APPLICATION

	
31

	
34.

	
RADON GAS

	
32

	
35.

	
MOLD

	
32

	
36.

	
PARKING

	
32

	
37.

	
SIGNAGE

	
33

	
38.

	
RIGHT OF ENTRY

	
33

	
39.

	
CERTAIN RIGHTS RESERVED TO LANDLORD

	
33

	
40.

	
LEASE COMMENCEMENT/ACCEPTANCE OF PREMISES

	
34

	
41.

	
WAIVER OF RIGHT TO JURY TRIAL

	
34

	
42.

	
RECORDING

	
34

	
43.

	
SUBORDINATION OF LANDLORD’S LIEN

	
34

	
44.

	
NO RELOCATION

	
34

 

ii

 

 

1.            TERMS.  Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1:

 

	
Effective Date:

	
October 5, 2018

 

	
Name of Tenant:

	
TherapeuticsMD, Inc., a Nevada corporation

 

	
Notice Address of Tenant:

(a)  Prior to possession:

	
 

6800 Broken Sound Parkway NW

3rd Floor

Boca Raton, Florida 33487

 

	
(b)  Following the Full Premises Commencement Date:

	
951 Yamato Road

Suite 160

Boca Raton, Florida 33431

 

	
Name of Landlord:

	
951 Yamato Acquisition Company, LLC

 

	
Notice Address of Landlord:

 

 

 

with a copy to:

	
138 Conant Street

Beverly, MA  01915

Attention:  Director of Asset Management

 

Michael C. Wilde, Esq.

BAKER & HOSTETLER LLP

SunTrust Center, Suite 2300

200 South Orange Avenue

Orlando, Florida 32801

 

	
Landlord’s Remittance Address:

	
951 Yamato Acquisition Company

P.O. Box 864885

Orlando, FL  32886-4885

 

	
Building:

	
The building located at

951 Yamato Road, Boca Raton, Florida

 

	
Property:

	
The Building and the real property on which the Building is located and any other buildings and improvements located thereon as shown on the site plan attached hereto as Exhibit A-1.  For all purposes under this Lease, the Property shall include all related site land, property, improvements, parking facilities, common areas, driveways, sidewalks and landscaping which form a part of the project located at 951 Yamato Road, Boca Raton, Florida 33431 and commonly known as 951 Yamato Road.

 

 

1

 

 

	
Premises:

	
Approximately 56,212 rentable square feet of space located on the first and second floors of the south wing of the Building and comprised of: (i) Suite 150 containing approximately 27,321 rentable square feet (“Suite 150”), (ii) Suite 220 containing approximately 21,330 rentable square feet (“Suite 220”) and (iii) Suite 160 on the first floor of the west wing containing approximately 7,561 rentable square footage (“Suite 160”), as shown by the floor plans attached hereto as Exhibit A.  The “rentable square footage” of the Premises shall be deemed to be 56,212 square feet for all purposes under this lease.  The usable square footage of the Premises has been measured in accordance with the American National Standard Method of Measuring Floor Area in Office Buildings of the Building Owners and Managers Association International (ANSI Z65.1-2010), provided the load factor is not calculated per BOMA.

 

	
Permitted Use:

	
General office use, and no other use or purpose.

 

	
Term:

	
The period of time beginning on the Suite 160 Commencement Date and ending at 11:59 P.M. on the Expiration Date.

 

	
Suite 160 Commencement Date:

	
Subject to the terms of Section 3 of the Lease, the earlier to occur of (i) October 27, 2018 or (ii) the date Tenant commences operation of its business in Suite 160.  Tenant shall confirm the Suite 160 Commencement Date pursuant to the terms herein.

 

	
Full Premises Commencement Date:

	
Subject to the terms of Section 3 of the Lease, the Full Premises Commencement Date shall be the earlier to occur of (i) “Substantial Completion” of the “Tenant Improvements” (as said terms are defined in the Work Letter attached as Exhibit F) but no earlier than June 1, 2019 or (ii) the date Tenant commences operation of its business in either Suite 150 or Suite 220.  Tenant shall confirm the Full Premises Commencement Date pursuant to the terms herein.

 

	
Expiration Date:

	
That certain date which is the last day of the one hundred thirty second (132nd) complete calendar month following the Full Premises Commencement Date.

 

	
Tenant’s Percentage:

	
[***]%, being the ratio of rentable square footage of the Premises to the total rentable square footage of the Building (currently [***] rentable square feet), provided that until the occurrence of the Full Premises Commencement Date the Tenant’s Percentage shall be [***]% (based on Suite 160).

 

 

2

 

 

	
Prepaid Rent:

	
$[***] (to be applied, pursuant to the terms herein), representing the amounts estimated for the first month in which rent is payable for the entire Premises (estimated to be $[***]) and the last month in which rent is payable for the entire Premises (estimated to be $[***]).  Provided that (i) Tenant has paid all amounts due and has otherwise performed all obligations hereunder, (ii) there exists no Event of Default hereunder, and (iii) this Lease is then in full force and effect, the Landlord shall credit the remaining portion of the Prepaid Rent (after deducting the amount for the first month’s rent) to the Rent payable for the month of January 2024, with such credit to be conditioned on (i), (ii), and (iii) above.  In the event the conditions above are not satisfied as of December 31, 2023, the remaining portion of the Prepaid Rent shall be held and credited to the last month of the Term.

 

	
Security Deposit:

	
$[***].

 

	
Exhibits:

	
Exhibit A-1          Site Plan of the Building

Exhibit A-2          Location of Parking Spaces

Exhibit A-3          Building Lot and Shared Lot

Exhibit A              The Premises

Exhibit B              Rules and Regulations

Exhibit C              Commencement Letter

Exhibit D              Additional Stipulations

Exhibit E              Suite 160 Work Letter

Exhibit F              Landlord Work Letter

Exhibit G             Intentionally Deleted

Exhibit H             Current Lender Form SNDA

Exhibit I               Assumed Rent Table

Exhibit J               Landlord’s Agreement

All of the Exhibits listed above are incorporated into and made part of this Lease. 

 

3

 

 

	
Rent:

	
Base Rent and all Additional Rent, plus all applicable sales tax thereon.

 

	
Additional Rent:

	
All amounts required to be paid by Tenant to Landlord pursuant to this Lease other than Base Rent, including, without limitation, Tenant’s Percentage of Operating Expenses and Taxes.

 

	
Base Rent:

	
Base Rent is at the initial rate of $[***] per rentable square foot, plus all applicable sales tax thereon, escalating annually at the rate of [***]% on each anniversary of the Suite 160 Commencement Date (as to the Base Rent for Suite 160) and each anniversary of the Full Premises Commencement Date (as to the Base Rent for Suite 150 and Suite 220) with the Term to expire at the end of the 132nd full month from the Full Premises Commencement Date.

 

Notwithstanding the foregoing, Base Rent and Tenant’s Percentage of Operating Expenses and Taxes for Suite 160 (7,561 rentable square feet) shall be abated for the first [***] ([***]) [***] period of the Term commencing on the Suite 160 Commencement Date (the “Suite 160 Rent Abatement Period”).  The Base Rent and Tenant’s Percentage of Operating Expenses and Taxes for Suite 160 due for any partial calendar month immediately following the Suite 160 Rent Abatement Period shall be prorated based on the number of days in that month.  Notwithstanding anything herein to the contrary, during the Suite 160 Rent Abatement Period, Tenant shall pay the Tenant’s Percentage of electricity for Suite 160 and Tenant’s Percentage of janitorial services for Suite 160 which is estimated to be $[***] psf, provided that Tenant’s Percentage of electricity and janitorial services shall be subject to reconciliation based upon the actual cost of the electricity and janitorial services, but in no event shall the cost exceed $[***] per rsf for calendar year 2018. 

 

Further, notwithstanding the foregoing, Base Rent and Tenant’s Percentage of Operating Expenses and Taxes for the Suite 150 (27,321 rentable square feet) and Suite 220 (21,330 rentable square feet) shall be abated for the [***] ([***]) [***] period commencing on the Full Premises Commencement Date (the “Suites 150 & 220 Rent Abatement Period”).  The Base Rent and Tenant’s Percentage of Operating Expenses and Taxes for Suites 150 & 220 due for any partial calendar month immediately following the Suites 150 & 220 Rent Abatement Period shall be prorated based on the number of days in that month.  Tenant shall pay the Tenant’s Percentage of electricity for Suite 150 and Suite 220 and Tenant’s Percentage of janitorial services for Suite 150 and Suite 220, which shall be based on 2019 budgets, provided that Tenant’s Percentage of electricity and janitorial services shall be subject to reconciliation based upon the actual cost of the electricity and janitorial services, but in no event shall the cost exceed $[***] per rsf for calendar year 2019.

 

2.           THE PREMISES.  Landlord leases to Tenant, and Tenant leases from Landlord, upon and subject to the terms and conditions of this Lease, the Premises together with certain rights to the Common Areas as hereinafter specified, it being acknowledged and agreed that the commencement dates for the respective suites of the Premises shall be staggered in accordance with the terms herein.  The term “Common Areas” is defined as all areas and facilities outside the Premises and within the exterior boundary line of the Property that are designated by Landlord from time to time for the general non-exclusive use of Landlord, Tenant and the other tenants of the Building and their respective employees, suppliers, customers and invitees, including, but not limited to, common entrances, lobbies, corridors, stairwells, public restrooms, conference rooms, elevators, parking areas, loading and unloading areas, roadways and sidewalks.

 

4

 

 

3.          
TERM.  The Premises, or applicable portion thereof as they case may be, are leased for the Term.  If for any reason
Landlord is unable to deliver possession of the Suite 160 Premises to Tenant on or prior to October 7, 2018 (subject to a
day-for-day extension due to Force Majeure), in addition to any other free rent periods as provided for in this Lease, Tenant
shall receive one day of free rent for each day in the period commencing on October 7, 2018 (subject to a day-for-day extension
due to Force Majeure) and ending on the date that Landlord delivers the Suite 160 Premises to Tenant.  If Landlord has
not completed the Phase 2 portion of the Landlord’s Suite 160 Work (as defined in Exhibit E) on or
before December 15, 2018 (subject to a day-for-day extension due to Force Majeure or Tenant Delay), in addition to any other free
rent periods as provided for in this Lease, Tenant shall receive one day of free rent for each day in the period commencing on
December 15, 2018 (subject to a day-for-day extension due to Force Majeure or Tenant Delay) and ending on the date that Landlord
completes the Phase 2 portion of the Landlord’s Suite 160 Work.  If for any reason Landlord is unable to
deliver possession of the Suite 150 & Suite 220 portion of the Premises to Tenant on or prior to July 1, 2019 (subject
to a day-for-day extension due to (i) Force Majeure, (ii) Tenant’s failure to fully approve of the plans for Tenant Improvements
by November 15, 2018, or (iii) Tenant Delay) in the condition required by the Work Letter, Tenant shall receive one day of free
rent for each day in the period commencing on July 1, 2019 (subject to a day-for-day extension due to (i) Force Majeure, (ii)
Tenant’s failure to fully approve of the plans for Tenant Improvements by November 15, 2018, or (iii) Tenant Delay) and
ending on the date that Landlord delivers the Suite 150 & Suite 220 portion of the Premises to Tenant in the condition
required by the Work Letter.

 

If
for any reason Landlord has not delivered the Suite 150 & Suite 220 portion of the Premises to Tenant on or prior to November
30, 2019 (subject to a day-for-day extension due to (i) Force Majeure, (ii) Tenant’s failure to fully approve of the plans
for Tenant Improvements by November 15, 2018, or (iii) Tenant Delay) in the condition required by the Work Letter, Tenant
shall have the right to terminate this Lease by providing written notice of such termination to Landlord on or before December
10, 2019.  Tenant shall have the option to extend the Term subject to the terms and conditions of Exhibit D attached
hereto.

 

4.          
CONDITION OF THE PREMISES.  Except as expressly set forth herein and in the Work Letter, the Premises are leased in an
“as is” and “where is” condition without any warranty of suitability, habitability or fitness for use,
occupation or any particular purpose express or implied, it being agreed that Tenant has had an opportunity to examine the condition
of the Premises, that Landlord has made no representations or warranties of any kind with respect to such condition, and that
except as expressly set forth herein and in the Work Letter, Landlord has no obligation to do or approve any work or make or approve
any improvements to or with respect to the Premises to prepare the same for Tenant’s occupancy except as expressly set
forth herein and in the Work Letter.  Landlord shall make improvements to the Suite 160 Premises and tender possession
of the Suite 160 Premises in accordance with the terms of the Work Letter attached as Exhibit E.  Landlord
shall make improvements to Suite 150 and Suite 220 and tender possession of Suite 150 and Suite 220 as described
in the Work Letter attached as Exhibit F.

 

5

 

 

5.           MONTHLY RENT.  Subject to the rent abatement periods provided herein, commencing on the Suite 160 Commencement Date and the Full Premises Commencement Date (respectively), Base Rent for the applicable portion of the Premises, plus applicable sales tax, shall be paid monthly in advance on or before the first day of each calendar month.  The Base Rent shall not be adjusted or modified if the actual rentable square footage of the Premises varies from the rentable square footage set forth herein by [***]% or less.  If the Suite 160 Commencement Date or the Full Premises Commencement Date (respectively) shall be on any day other than the first day of a calendar month, Base Rent, plus applicable sales tax, for the partial month shall be prorated based on the number of days in that month.  Unless otherwise provided herein, commencing on the Suite 160 Commencement Date and the Full Premises Commencement Date (respectively), Additional Rent, plus applicable sales tax, shall also be paid monthly in advance on or before the first day of each calendar month.  If the Suite 160 Commencement Date or the Full Premises Commencement Date (respectively) shall be on any day other than the first day of a calendar month, Additional Rent, plus applicable sales tax, for the partial month shall be prorated based on the number of days in that month.  Rent shall be paid to Landlord, without notice or demand, and without deduction or offset, in lawful money of the United States of America, at Landlord’s Remittance Address as set forth in Section 1 or to such other address as Landlord may from time to time designate in writing.  Tenant acknowledges that the late payment of Rent or other sums due hereunder shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult to ascertain.  Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed on Landlord by the terms of any mortgage or trust deed covering the Property.  Accordingly, if any installment of Rent or any other sums due from Tenant shall not be received by Landlord within [***] ([***]) days of when due, Tenant shall pay to Landlord a late charge equal to [***] percent ([***]%) of such overdue amount.  In addition, any amount due to Landlord, if not paid within [***] ([***]) days of when due, shall bear interest from the date due until paid at the lesser of: (i) the Prime Rate (as hereinafter defined) plus [***] percent ([***]%) per annum, or (ii) the highest rate permitted by law (the “Default Rate”).  The term “Prime Rate” shall mean the Prime Rate as published in The Wall Street Journal from time to time.  The parties agree that such late charges represent a fair and reasonable estimate of the costs Landlord shall incur by reason of late payment by Tenant.  The acceptance of such late charges by Landlord shall in no event constitute a waiver of Tenant’s default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies granted hereunder.  Notwithstanding anything to the contrary in this Lease, Tenant shall pay the Prepaid Rent simultaneously with Tenant’s execution and delivery of this Lease.  Notwithstanding the foregoing, Landlord shall not charge Tenant interest or late charges for the first late payment in any [***] ([***]) month period provided that Tenant pays any all sums due within [***] ([***]) days of the date due, with any subsequent late payment to incur fees and interest without any additional grace period.

 

Notwithstanding anything to the contrary, at the expiration of any rent abatement period, Landlord shall apply the portion of the Prepaid Rent (as apportioned to Suite 160 after the expiration of the Suite 160 Rent Abatement Period and to Suites 150 and 220 after expiration of the Suites 150 and 220 Rent Abatement Period) applicable to the first month in which Rent is payable to Landlord, and Tenant shall not be obligated to pay Rent for that month, unless the amount of the Prepaid Rent is insufficient to cover the entire amount of the actual Rent due in which case Tenant will be obligated to pay the additional amount owed upon the same terms and at the same time such payment would otherwise be due.  The remaining amount of any Prepaid Rent shall be credited or applied as set forth above.

 

6

 

 

6.           TAXES.  Tenant shall pay monthly, as Additional Rent, one-twelfth (1/12) of Tenant’s Percentage of annual Taxes based on estimates provided by Landlord from time to time and subject to reconciliation as provided in Section 8 below.  “Taxes” means all taxes, assessments and fees levied upon the Property by any governmental entity based upon the ownership, leasing, renting or operation of the Property.  Taxes shall not include any federal, state or local net income, capital stock, succession, transfer, replacement, gift, estate or inheritance taxes; provided, however, if at any time during the Term, a tax or excise on income is levied or assessed by any governmental entity in lieu of or as a substitute for, in whole or in part, real estate taxes or other ad valorem taxes, such tax shall constitute and be included in Taxes.  In addition to the foregoing, Tenant shall pay Landlord, as Additional Rent, for any use, rent or sales tax, service tax, value added tax, franchise tax or any other tax on Rent however designated as well as for any taxes which are reasonably attributable to the cost or value of Tenant’s equipment, furniture, fixtures and other personal property located in the Premises or the cost or value of any leasehold improvements made in or to the Premises by or for Tenant.  All expenses, including attorneys’ fees and disbursements, experts’ and other witnesses’ fees, incurred in contesting the validity or amount of any Taxes or in obtaining a refund of Taxes shall be considered as part of the Taxes for the year in which the expenses are incurred.  For property tax purposes, to the extent allowed by Law, Tenant waives all rights to protest or appeal the appraised value of the Premises, as well as the Property, and all rights to receive notices of reappraisement.

 

Landlord may, in Landlord’s commercially reasonable opinion, contest the real property Taxes assessed against the Building on an annual basis and, upon Tenant’s request, Landlord and Tenant shall meet to discuss such contest and Landlord shall share such information that Landlord may have obtained relative to any recommendation from a tax consultant.  All costs incurred by Landlord in seeking to obtain a real property Tax reduction shall be considered an Operating Expense.

 

7

 

 

7.           OPERATING EXPENSES.  Tenant shall pay monthly, as Additional Rent, one-twelfth (1/12) of Tenant’s Percentage of annual Operating Expenses based on commercially reasonable estimates provided by Landlord on or about each January 1 during the term of this Lease and subject to reconciliation as provided in Section 8 below.  “Operating Expenses” means and includes, but is not limited to:  (a) all expenses paid or incurred by Landlord for ownership, maintaining, operating and repairing the Property, and all other systems and components of the Building, its parking areas, the curbs, sidewalks and plazas adjoining the same, including, but not limited to, the cost of painting, cleaning, refurbishing, re-carpeting, redecorating, gardening, planting, seeding and maintenance of landscaped areas, trash removal, drain maintenance, assessments, expenses and contributions in connection with the City of Boca Raton’s Transportation Demand Management Programs, security guard service and Building security access, exterior maintenance of the improvements, window cleaning, janitorial service, uniforms, management fees, supplies and sundries; (b) utility expenses incurred by Landlord in furnishing utility services for the Property, including the cost of electricity, gas or other fuel, heating, lighting, air conditioning, sewer and waste water service and general surface drainage; (c) those expenses paid or incurred by Landlord for insurance, including, but not limited to, fire, extended coverage, liability, workers compensation, elevator, or any other insurance carried in good faith by Landlord and applicable to the Property; (d) the cost of rental of all supplies, tools, materials and equipment, including expenses paid or incurred by Landlord for sales or use taxes on supplies or services; (e) the cost of wages and salaries of all persons engaged in the operation, maintenance and repair of the Property, and so-called fringe benefits, including social security taxes, unemployment insurance taxes, cost for providing coverage for disability benefits, cost of any pensions, hospitalization, welfare or retirement plans, or any other similar or like expenses incurred under the provisions of any collective bargaining agreement, or any other cost of expense which Landlord pays or incurs to provide benefits for employees so engaged in the operation, maintenance and repair of the Property; (f) the charges of any independent contractor who, under contract with Landlord or its representatives, does any of the work of operating, maintaining or repairing the Property, including without limitation, the charges for services, materials and supplies furnished in connection with the operation, maintenance or repair of any part of the Building or the heating, air conditioning, ventilating, plumbing, roofing, electrical, elevator, escalators, fire detection systems (including sprinklers) and other systems of the Building; (g) depreciation of hand tools and other moveable equipment used in the repair, maintenance or operation of the Property; (h) legal, accounting, and other professional expenses incurred in connection with the operation, maintenance and management of the Property, including, but not limited to, such expenses as relate to seeking refunds of or obtaining reductions in the taxes; (i) the costs of any capital improvement or alteration, together with any financing charges incurred in connection therewith, made to the Property which is either required by a change in or enactment of any new law (or governmental regulation) after the Effective Date or intended by Landlord to reduce operating costs or expenses, it being understood that such costs shall be amortized over their useful life as reasonable determined by Landlord; and (j) the cost of any other service provided by Landlord or any cost that is elsewhere stated in this Lease to be an “Operating Expense”.  Landlord may allocate any item of Operating Expenses among different portions or occupants of the Building or Property based on use or other considerations as determined by Landlord in Landlord’s reasonable discretion.  If during any calendar year, any rentable space in the Building shall be vacant or unoccupied, at Landlord’s option, the Operating Expense for such calendar year which vary with occupancy shall be adjusted to reflect the expenses that would have been incurred if such space had been occupied.  If any Operating Expense, though paid in one (1) year, relates to more than one (1) calendar year, at the option of the Landlord such expense may be proportionately allocated among such related calendar years.  

 

Notwithstanding the foregoing, Operating Expenses shall not include:

 

(i)           Ground lease rental payments;

 

(ii)          Costs incurred by Landlord for the repair of damage to the Building to the extent that Landlord is reimbursed by insurance proceeds;

 

8

 

 

(iii)       Costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for tenants or other occupants in the Building or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Building;

 

(iv)        Marketing costs including leasing commissions, attorneys’ fees in connection with the negotiation and preparation of letters, deal memos, letters of intent, leases, subleases and/or assignments, space planning costs, and other costs and expenses incurred in connection with lease, sublease and/or assignment negotiations and transactions or the enforcement of the terms of any leases or subleases with present or prospective tenants or other occupants of the Building;

 

(v)         Expenses in connection with services or other benefits which are not offered to Tenant or for which Tenant is charged for directly but which are provided to another tenant or occupant of the Building;

 

(vi)        Overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in the Building to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis;

 

(vii)       Interest, principal, points and fees on debts or amortization on any mortgage or mortgages or any other debt instrument encumbering the Building;

 

(viii)      Landlord’s general corporate overhead and general and administrative expenses;

 

(ix)        Any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord;

 

(x)         Advertising and promotional expenditures, and costs of signs in or on the building identifying the owner of the Building or other tenants’ signs, other than directional signs,  the building directory and maintenance of the Building’s monument sign;

 

(xi)        Property management fees in excess of the rates then customarily charged for building management by property managers with equal or better qualifications for buildings of like class and character;

 

(xii)       Penalties for the late payment of any taxes (provided that Tenant is not the cause of such late payment);

 

(xiii)      Wages, cost, and salaries associated with home office, off-site employees of Landlord and wages, cost and salaries attributable to persons above the level of “General Manager”;

 

(xiv)      The cost of separate metering and/or tap in charges for utilities for other tenants of Building;

 

9

 

 

(xv)       The cost of correcting defects in the design or construction of or latent defects in the Premises or the Building, including repair or replacement of any item actually paid for or completed under a warranty, except that conditions (not occasioned by construction defects) resulting from ordinary wear and tear will not be deemed defects for the purpose of this category;

 

(xvi)      Except as specifically permitted under this Lease, the cost of any repairs, alterations, additions, changes, replacements, and other items which under generally accepted accounting principles are properly classified as capital expenditures or capital improvements;

 

(xvii)      The cost of tools and equipment used initially in the construction, of the Building;

 

(xviii)    The cost of removal, abatement, or treatment of asbestos or any other hazardous substance, including any amounts expended by Landlord as environmental response costs for removal, enclosure, encapsulation, clean-up, remediation or other activities regarding Landlord’s compliance with federal, state, municipal or local hazardous waste and environmental laws, regulations or ordinances;

 

(xix)       Charitable and political contributions of Landlord; and

 

(xx)        Cost and maintenance of paintings, sculptures or other art work leased and/or purchased for display at the Building.

 

Notwithstanding anything to the contrary contained in this Section 7, Tenant’s total Operating Expense payment obligations for all Operating Expenses other than security costs, insurance premiums, utilities, uninsured costs related to weather related events (but in no event more than $[***] per year), and real property taxes shall not increase by more than [***] percent ([***]%) (on a cumulative and compounded basis) over the sum paid by Tenant in the immediately preceding full calendar year.  In the event that the immediately preceding calendar year is not a full calendar year, the Operating Expenses shall be equitably estimated so as to approximate the cost for a full calendar year.  Any increases in Operating Expenses not recovered by Landlord due to the foregoing limitation may be carried forward into all succeeding calendar years during the Term (on a cumulative and compounded basis) until fully recouped by Landlord.

 

8.          RECONCILIATION.  Landlord shall deliver to Tenant within one hundred twenty (120) days after the expiration of each calendar year a reasonably detailed statement (the “Statement”) showing Tenant’s Percentage of the actual Operating Expenses incurred during such year.  Except as otherwise set forth below, Landlord’s failure to deliver the Statement to Tenant within said period shall not constitute Landlord’s waiver of its right to collect said amounts or otherwise prejudice Landlord’s rights hereunder.  If Tenant’s payments under this Section 8 during said year exceed Tenant’s Percentage of Operating Expenses as indicated on the Statement (the “Operating Expense Overstatement”), Landlord shall credit the amount of such overpayment against such payment of Rent next falling due, or, if the Term will expire before the overpayment is fully credited, Landlord shall pay such difference to Tenant within [***] ([***]) days of the determination of such Operating Expense Overstatement.  If Tenant’s payments under this Section 7 during said year were less than Tenant’s Percentage as indicated on the Statement, Tenant shall pay to Landlord the amount of the deficiency within [***] ([***]) days after delivery by Landlord to Tenant of the Statement. Landlord and Tenant shall forthwith adjust between them by cash payment any balance determined to exist with respect to that portion of the last year of the Lease Term for which Tenant is responsible for Operating Expenses, notwithstanding that the Lease Term may have terminated before the end of such year. The obligations set forth in this subsection shall survive the expiration, or earlier termination, of this Lease.

 

10

 

 

Provided Tenant is not then in default beyond applicable notice and cure periods and has paid the Operating Expenses shown on the Statement, if Tenant disputes the amount set forth in the Statement, Tenant shall have the right, at Tenant’s sole expense, not later than [***] ([***]) days following receipt of such Statement, to cause Landlord’s books and records with respect to the calendar year which is the subject of the Statement to be audited by a certified public accountant mutually acceptable to Landlord and Tenant); provided, however, Landlord’s approval shall not be unreasonably withheld, and the [***] ([***]) day period shall be tolled for the period during which Landlord is determining whether to approve such certified public accountant.  The audit shall take place at the offices of Landlord where its books and records are located at a mutually convenient time during Landlord’s regular business hours in Palm Beach County, Florida.   The accountant conducting the audit shall be compensated on an hourly basis and shall not be compensated based upon a percentage of overcharges it discovers.  If Tenant gives Landlord notice of its intention to audit Operating Expenses, it must commence such audit within [***] ([***]) days after such notice is delivered to Landlord, and the audit must be completed within [***] ([***]) days after such notice is delivered to Landlord.  If Tenant does not commence and complete the audit within such periods, the Statement that Tenant elected to audit shall be deemed final and binding upon Tenant and shall, as between the parties, be conclusively deemed correct. Tenant will use good faith commercially reasonable efforts to keep the results of any Operating Expense audit confidential. Upon Landlord’s receipt of a timely objection notice from Tenant, Landlord and Tenant shall work together in good faith to resolve the discrepancy between Landlord’s statement and Tenant’s review.  If Landlord and Tenant determine that Operating Expenses for the year in question are less than reported in Landlord’s statement, Landlord shall provide Tenant with a credit against future Rent in the amount of any overpayment by Tenant.  Likewise, if Landlord and Tenant determine that Operating Expenses for the year in question are greater than reported in Landlord’s statement, Tenant shall forthwith pay to Landlord the amount of underpayment by Tenant.  If after Landlord and Tenant agree on the results of any audit of Landlord’s books and records indicates that Landlord has made an error in Landlord’s favor for more than [***] percent ([***]%) of the amount of Operating Expenses for any calendar year, Landlord shall reimburse Tenant for Tenant’s reasonable costs of conducting the audit up to a maximum of $[***].  In addition, Landlord shall pay to Tenant an amount equal to such overstated amounts, which sums shall be paid within [***] ([***]) days of Tenant’s demand therefore.  If such payment is not received by Tenant prior to the expiration of such [***] ([***]) day period, Tenant may withold such amount from future payments of Rent until such amount is reduced to 0.00.

 

Notwithstanding any provision in this Lease to the contrary, Landlord shall not be entitled to collect any charge or expense for Operating Expenses if Landlord has not presented Tenant with a billing within [***] ([***]) years after the date such charge or expense was incurred.

 

11

 

 

9.            INSURANCE. 

 

(A)         Tenant shall maintain the following insurance in force from the date upon which Tenant first enters the Premises and throughout the Term and thereafter for so long as Tenant is in occupancy of any part of the Premises: 

 

(i)          Commercial
General Liability insurance with limits of at least $[***] per occurrence, $[***] general aggregate, and, if the Tenant
manufacturers or produces a product, $[***] products completed operations aggregate or such larger amounts as Landlord may
reasonably require from time to time, covering bodily injury and property damage arising out of the use of the Premises, as
well as products/completed operations, blanket contractual liability, personal injury and advertising liability;

 

(ii)         Worker’s Compensation insurance as required by the state in which the Premises is located covering occupational injuries or disease to all employees of Tenant and to any contractors, subcontractors or other agents used by Tenant for work or other activities on or about the Premises.  If such insurance is not required by the state in which the Premises is located, then, and in any event, Tenant shall maintain such insurance with Employer’s Liability limits of at least $[***] each accident, $[***] each employee, and $[***] disease;

 

(iii)        Business Automobile Liability insurance for all owned (Symbol 1), non-owned (Symbol 9) hired, rented and/or borrowed (Symbol 8) vehicles used by the Tenant, its employees or agents.  Such policy shall include a combined single limit of liability of at least $[***] per claim for bodily injury and property damage;

 

(iv)        Excess or Umbrella Liability insurance with a limit of at least $[***] providing additional limits of insurance over the primary per occurrence and aggregate limits of the Commercial General Liability (including bodily injury, property damage, products/completed operations, personal/advertising injury and blanket contractual liability); and

 

(v)         Property insurance covering “all risk” of physical damage to Tenant’s personal property.

 

(B)         Tenant’s Commercial General Liability, Property, and Excess Liability/Umbrella Liability policies shall name Landlord and Landlord’s managing agent and any mortgagee that Landlord has provided the name of to Tenant, as Additional Insureds and the Commercial General Liability and Excess Liability/Umbrella Liability shall be primary and non-contributory insurance as to any insurance carried by the parties designated as Additional Insureds.  All policies purchased and maintained by Tenant to satisfy the requirements in this Lease must be purchased from an insurance company with a minimum rating of “A- X” or its equivalent from one of the major rating agencies (AM Best, Moodys, Standard & Poors, Fitch) that is admitted or eligible to do business in the state where the Premises is located.

 

(C)         Tenant shall provide Landlord with a certificate of insurance for each policy simultaneously with the delivery of an executed counterpart of this Lease and at least [***] ([***]) days prior to each renewal of such insurance.  Such certificates of insurance shall be on an ACORD Form 25 or ISO Form 2026 or their equivalent, shall certify that such policy has been or shall be issued and that it provides the coverage and limits required above, and shall provide that the insurance shall not be canceled or materially changed unless [***] ([***]) days prior written notice shall have been given to Landlord.  Tenant shall notify Landlord in writing at least [***] ([***]) days in advance if Tenant intends to or receives a notice that its insurance company intends to cancel or non-renew such insurance for any reason, or if the required coverage or limits are to be materially changed from the initial requirements in this Lease.  In the event that the applicable statutory time period is less than [***] ([***]) days, then Tenant shall notify Landlord within [***] ([***]) business days of receipt of any cancellation or non-renew notice.  In the event that Tenant fails to obtain or maintain the insurance required above or fails to provide the Certificates of Insurance required, Landlord may, at its option, after providing Tenant with written notice and a reasonable opportunity to cure, obtain such insurance on behalf of Tenant.  Tenant shall pay, as Additional Rent within [***] ([***]) days after Landlord’s written demand, the reasonable cost of such insurance.  Landlord’s failure to obtain such coverage on behalf of Tenant shall not limit Tenant’s liability in the event of an uncovered loss. 

 

12

 

 

(D)        Landlord shall carry or cause to be carried property insurance for full replacement cost and commercial general liability insurance in amounts and with deductibles as a reasonably prudent owner of a building similar to the Building in the geographic vicinity of the Building (“Comparable Building”) would purchase and maintain with respect to the Property.  Tenant shall pay Tenant’s Percentage of Landlord’s insurance premiums (“Insurance Premiums”) during the Term of the Lease as a part of Operating Expenses.  If Tenant does conduct any activity within or about the Premises that result in an increase to the cost of Landlord’s insurance Tenant shall reimburse Landlord for the entire amount of such additional premiums or surcharges within [***] ([***]) days after Landlord’s written demand.

 

(E)        The limits of insurance required by this Lease, or as carried by Tenant, will not limit the liability of Tenant or relieve Tenant of any obligation hereunder, except to the extent provided for under Section 10 below (Subrogation).  Any deductibles selected by Tenant will be the sole responsibility of Tenant.

 

(F)         Landlord may, at its sole discretion, change the insurance policy limits and forms which are required to be provided by Tenant; such changes will be made to conform with common insurance requirements for Comparable Buildings if commercially reasonably available.

 

10.        WAIVER OF SUBROGATION.  All provisions of this Lease to the contrary notwith­standing, Landlord waives any and all rights of recovery against Tenant, Tenant’s employees, agents and contractors for or arising out of damage to, or destruction of the Building, the Premises or Landlord’s personal property to the extent that such damage or destruction is covered by Landlord’s insurance policies then in effect or the insurance policies Landlord is required to obtain by Section 9 (whether or not the insurance Landlord is required to obtain by Section 9 is then in force and effect), whichever is broader.  Landlord’s waiver shall not be limited by the amount of insurance then carried by Landlord.  All provisions of this Lease to the contrary notwithstanding, Tenant waives any and all rights of recovery against Landlord, Landlord’s employees, agents and contractors for loss or damage to the Premises and Tenant’s personal property to the extent such liability or damage is covered by Tenant’s insurance policies then in force or the insurance policies Tenant is required to obtain by Section 9 (whether or not the insurance Tenant is required to obtain by Section 9 is then in force and effect), whichever is broader.  Tenant’s waiver shall not be limited by the amount of insurance then carried by Tenant.  Each party shall cause the property insurance policies it obtains in accordance with Section 9 to provide that the insurance company waives all right of recovery by subrogation against the other party in connection with any liability or damage covered by such insurance policies.  If necessary to effect the foregoing waivers, Landlord and Tenant hereby agree to cause an endorsement to be issued to their respective insurance policies (including any contents, fire and casualty insurance) recognizing this waiver of subrogation; provided, however, that failure to obtain such endorsements shall not affect the releases hereinabove given.

 

13

 

 

11.         SECURITY DEPOSIT.  Upon execution of this Lease, Tenant shall deposit with Landlord the amount of the Security Deposit specified in Section 1 of this Lease.  Provided that Tenant has paid all amounts due and has otherwise performed all obligations hereunder, the Security Deposit shall be returned to Tenant without interest within [***] ([***]) days of the expiration of the Term, further provided that Landlord may deduct from the Security Deposit prior to returning it any amounts owed by Tenant to Landlord.  If Tenant defaults under any provision of this Lease, Landlord may, but shall not be obligated to, apply all or any part of the Security Deposit to cure the default.  In the event Landlord elects to apply the Security Deposit as provided for above, Tenant shall, within [***] ([***]) business days after Landlord’s demand, restore the Security Deposit to the original amount.  Landlord may, at its discretion, commingle the Security Deposit with its other funds.  Upon any sale or other conveyance of the Building, Landlord may transfer the Security Deposit (or any amount of the Security Deposit remaining) to a successor owner, and upon such successor’s actual receipt of the Security Deposit (or any amount of the Security Deposit remaining) Tenant agrees to look solely to the successor owner for repayment of the same.  The Security Deposit shall not operate as a limitation on any recovery to which Landlord may be entitled.

 

12.         USE.  The Premises shall be used for the Permitted Use and for no other purposes whatsoever.  Tenant shall not do or permit to be done in or about the Premises, Building or Property anything which is prohibited by any ordinance, order, rule, regulation, certificate of occupancy, or other governmental requirement, now in force or which may hereafter be enacted, including, without limitation, the Americans with Disabilities Act of 1990, as amended (collectively, “Applicable Law”).  Tenant shall comply with all Applicable Law that applies to Tenant’s use or occupation of the Premises and common areas of the Property.  Tenant shall use and cause all contractors, agents, employees, invitees and visitors of Tenant to use the Premises and any common area of the Property in such a manner as to prevent waste, nuisance and any disruption of other occupants.  Tenant shall not place a load upon any floor in the Premises exceeding the floor load per square foot of area which such floor was designed to carry or which is allowed by law.  The judgment of any court of competent jurisdiction or the admission by Tenant in any action or proceeding against Tenant, whether Landlord is a party thereto or not, that Tenant has violated any Applicable Law in the use or occupancy of the Premises, Building or Property shall be conclusive of that fact as between Landlord and Tenant.

 

14

 

 

13.         MAINTENANCE; SERVICES.  Excepting only those obligations for which Landlord is expressly responsible pursuant to this section, Tenant will, throughout the Term and at its sole cost, keep and maintain the interior of the Premises and all fixtures and equipment located therein, including, without limitation, carpeting, wall-covering, doors, plumbing and other fixtures, and any alterations performed for the benefit of the Premises, clean safe and in good working order, condition and repair and make all necessary repairs and replacements thereto, including, without limitation, replacing all interior broken glass with glass of the same size and quality as that broken and maintain all systems or portions of systems exclusively serving the Premises including, without limitation, electrical, mechanical, plumbing and heating, ventilating and air conditioning systems.  All repairs and replacements required of Tenant in connection herewith shall be of a quality and class at least equal to the minimum building standards established by Landlord and shall be done in a good and workmanlike manner in compliance with all applicable laws and the terms and conditions of this Lease.  If Tenant fails to maintain the Premises in compliance with the terms hereof, Landlord shall have the right after written notice to do such acts and expend such funds at the expense of Tenant as are reasonably required and Tenant shall reimburse Landlord for the cost thereof as Additional Rent within [***] ([***]) business days after written demand.  In the event Tenant shall request that it be allowed to consume, or actually does consume electrical services in excess of that so determined by Landlord to be reasonable for office use, Landlord may require that upgraded supply facilities, panels and/or sub-meters be installed at Tenant’s expense.  Tenant agrees not to connect with water pipes any apparatus using water without consent of Landlord.  Tenant shall not be permitted to install any equipment causing a floor load in excess of eighty (80) pounds per square foot.  Landlord’s may, in its reasonable discretion, grant Tenant the right to exceed the floor loading capacity stated above in certain portions of the Building.

 

Should Tenant require any additional service not provided by Landlord pursuant to this Lease, Landlord shall reasonably cooperate with Tenant to obtain such additional service and Tenant agrees to pay Landlord’s charges therefor, including a reasonable administrative fee, any taxes imposed thereon, and, where appropriate, a reasonable allowance for depreciation of any systems being used to provide such service, as Additional Rent within [***] ([***]) days after Landlord’s written demand.  Landlord will provide afterhours HVAC upon Tenant’s request subject to limitations due to reasonable maintenance and repair on such systems and Force Majeure.  The current charge for after-hours HVAC usage is $[***] per hour, subject to adjustment from time to time by Landlord but not more than [***]% per year, on a cumulative and compounded basis.

 

If there is a tenant in the Building that will consume electricity materially beyond that of a typical office tenant, Landlord shall equitably allocate the total cost of electricity for the Building to all tenants and shall require the tenant that is consuming electricity materially beyond that of a typical office tenant to pay an increase in its electricity costs.

 

If the Premises contains supplemental HVAC equipment which is sub metered, Tenant shall be responsible to pay the cost for the same.  During the Term, Tenant shall be solely responsible for maintaining any supplemental HVAC equipment in good condition and repair at Tenant’s sole cost and expense, and Tenant shall reimburse Landlord for all electricity consumed by the supplemental HVAC equipment, as Additional Rent, within [***] ([***]) days after Tenant’s receipt of Landlord’s invoice for same.

 

Landlord shall maintain the roof, foundation, exterior walls, structural portions of the Building, elevators, if any, any Common Areas and electrical, plumbing, mechanical and fire protection systems (subject to systems exclusive to the Premises such as dishwashers) of the Building, the cost of which shall be included as a part of Operating Expenses, provided that Landlord shall have no obligation to make any repairs unless Landlord has first received written notice of the need for such repairs from Tenant.  Notwithstanding the foregoing and subject to the terms herein, any damage to the Property occasioned by the negligence or willful act of Tenant or any person claiming under Tenant, or contractors, agents, employees, invitees or visitors of Tenant or any such person, shall be repaired by and at the sole expense of Tenant, except that Landlord shall have the right, at its sole option, to make such repairs and to charge Tenant for all costs and expenses incurred in connection therewith and Tenant shall pay the cost therefor as Additional Rent within [***] ([***]) days after Landlord’s written demand.  Landlord shall not be responsible to maintain any additional air conditioning equipment particular to the Premises, such as air conditioning units located in a computer room or other utility area, or for any plumbing particular to the Premises, such as a break room or restroom located within the Premises.

 

15

 

 

In addition to the foregoing, during normal hours of operation of the Building throughout the Term, Landlord shall provide: (i) reasonable quantities of electricity for the common areas; (ii) electricity for Tenant’s normal office use; (iii) heating, ventilation and air conditioning as required in Landlord’s reasonable judgment for the comfortable use and occupancy of the Premises during the normal hours of operation of the Building; (iv) building standard window washing and janitorial services; (v) water for drinking, cleaning and restroom purposes only, and (vi) such other services as Landlord reasonably determines are necessary or appropriate.  The normal hours of operation of the Building shall be 8:00 a.m. to 6:00 p.m. on Monday through Friday (except holidays) and 9:00 a.m. to 1:00 p.m. on Saturday (except holidays).  Upon Tenant’s request, Landlord shall replace Building standard bulbs and ballasts in the Premises (to be included in Operating Expenses).

 

14.         SUBLEASE; ASSIGNMENT.  Tenant shall not mortgage, pledge, hypothecate or otherwise encumber its interest in this Lease without Landlord’s consent, which will not be unreasonably withheld, conditional or delayed.  Except in connection with a Permitted Transfer (as hereinafter defined), Tenant shall not allow the Premises to be occupied, in whole or in part, by any other party and shall neither sublet the Premises, in whole or in part, nor assign this Lease, nor amend any sublease or assignment to which Landlord has consented, without in each case obtaining the prior written consent of Landlord.  Any sublease or assignment, or amendment to any sublease or assignment, without Landlord’s prior written consent shall, at Landlord’s option, be null, void and of no effect, and shall, at Landlord’s option, constitute an Event of Default.  Except in connection with a Permitted Transfer, the provisions of this section shall apply to a transfer, by one or more transfers, of all, or substantially all, of the business or assets of Tenant, of a majority of the stock, partnership or membership interests, or other evidences of ownership, of Tenant, and of any shares, voting rights or ownership interests of Tenant which results in a change in the identity of the entity or entities which exercise, or may exercise, effective control of Tenant as if such transfers were an assignment of this Lease.  Tenant must request Landlord’s consent to any assignment or sublease at least [***] ([***]) days prior to the proposed effective date of the assignment or sublease.  At the time of its request, Tenant shall provide Landlord in writing: (a) the name and address of the proposed assignee or subtenant, (b) a complete copy of the proposed assignment or sublease, (c) reasonably satisfactory information about the nature, business, and business history of the proposed assignee or subtenant and its proposed use of the Premises, and (d) banking, financial or other credit information about the proposed assignee or subtenant sufficient to enable Landlord to determine its financial condition and operating performance.  Concurrently with such request, Tenant shall pay to Landlord a fee of $[***] to defray Landlord’s expenses in reviewing such request.  Landlord shall not unreasonably withhold or delay its consent to Tenant’s written request to sublease the Premises or assign this Lease which is made in compliance with the terms and conditions of this section.  Without limiting the other instances in which it may be reasonable for Landlord to withhold its consent to an assignment or sublease, Landlord’s refusal to consent to any proposed assignment or sublease shall not be unreasonable if:  (a) the financial condition or operating performance of the proposed subtenant or assignee, determined in Landlord’s reasonable discretion does not meet Landlord’s then existing Leasing criteria, (b) Tenant is in default under any of the terms, covenants or conditions of this Lease beyond applicable notice and cure periods, (c) the proposed use of the Premises may result in increased wear and tear on the Premises or the Building, (d) the proposed subtenant or assignee is a governmental agency, (e) Landlord has comparable space available elsewhere in the Building which can accommodate the needs of the proposed subtenant or assignee or the proposed subtenant and the assignee is a prospect to whom Landlord has made a proposal for the lease of space within the Building within the prior [***] ([***]) months, (f) the proposed subtenant or assignee would cause Landlord to be in violation of any covenant or restriction contained in another lease or other agreement, or (h) Landlord’s lender, if any, does not consent to the proposed sublease or assignment.

 

16

 

 

No subletting or assignment shall release Tenant from Tenant’s obligations under this Lease or alter the primary liability of Tenant to pay the Rent and to perform all other obligations to be performed by Tenant hereunder.  Any subtenant shall, at Landlord’s election, attorn to Landlord following any early termination of this Lease and any assignee shall be jointly and severally liable for the full performance of all of Tenant’s obligations hereunder.  Landlord may require, as a condition to granting Landlord’s consent with respect to the provisions of this section, that the proposed subtenant or assignee enter into a written agreement with Landlord confirming the obligations of such subtenant or assignee under this Lease.  If Tenant receives rent or other payments under any assignment or sublease in excess of the payments made by Tenant to Landlord under this Lease (as such amounts are adjusted on a per square foot basis if less than all of the Premises is transferred), then Tenant shall pay Landlord [***] ([***]%) of such excess after first deducing the reasonable and customary third party costs incurred by Tenant to effectuate the transfer.  Landlord’s consent to one assignment or sublease shall not be deemed a waiver of the requirement of Landlord’s consent to any subsequent assignment or sublease.

 

Notwithstanding anything to the contrary contained in this Section 14, provided Tenant is not in default beyond applicable notice and cure periods, Tenant may assign this Lease or sublet the Premises (or a portion thereof) in connection with any of the following without the prior written consent of Landlord (and without being required to pay any excess rents to Landlord), each a “Permitted Transfer” to an entity (each a “Permitted Transferee”) in connection with: (i) a sale of all or substantially all of Tenant’s assets or stock to an unrelated entity, (ii) any merger, consolidation, reorganization or similar transaction, (iii) any assignment or sublease to an Affiliate, or (iv) any transfer of stock whenever Tenant is a corporation, the outstanding stock of which is listed on a recognized national stock exchange.  The term “Affiliate” as used in this Section 14, shall mean any person or entity that is, directly or indirectly, controlled by, under common control with, or controlling, another person or entity.  Tenant acknowledges and agrees that any such assignment or sublease shall not release Tenant from Tenant’s obligations hereunder or alter the primary liability of Tenant to pay the Rent and other sums due Landlord hereunder and to perform all other obligations to be performed by Tenant hereunder.  In such event, Tenant must give Landlord at least [***] ([***]) days prior written notice with respect to any such Permitted Transfer.

 

17

 

 

15.         INDEMNITY; NON-LIABILITY OF LANDLORD.

 

(A)         Subject to the terms of Section 10 hereof, and except to the extent caused by the negligence or willful misconduct of an Indemnified Party, Tenant hereby agrees to indemnify, defend and hold harmless Landlord and its employees, partners, agents, members, managers, lenders and ground lessors (said persons and entities are hereinafter collectively referred to as the “Indemnified Parties”) from and against any and all liability, loss, cost, damage, claims, loss of rents, liens, judgments, penalties, fines, settlement costs, investigation costs, the reasonable cost of consultants and experts, reasonable attorneys’ fees, court costs and other legal expenses,  insurance policy deductibles and other reasonable expenses (hereinafter collectively referred to as “Damages”) arising out of or related to an “Indemnified Matter” (as defined below).  For purposes of this Section 15, an “Indemnified Matter” shall mean any matter for which one or more of the Indemnified Parties incurs liability or Damages if the liability or Damages are caused by (a) any negligent act or omission or willful misconduct of Tenant or its employees, agents, assignees, subtenants, licensees, contractors or invitees (all of said persons or entities are hereinafter collectively referred to as “Tenant Parties”), (b) Tenant’s failure to perform any of its obligations under the Lease (which failure continues after the passage of any applicable notice and cure period under the Lease), (c) the use or occupancy of the Premises by Tenant or any person claiming under Tenant, and/or (d) any other matters for which Tenant has agreed to indemnify Landlord pursuant to any other provision of this Lease.  Tenant’s obligations hereunder shall include, but shall not be limited to, compensating the Indemnified Parties for Damages arising out of Indemnified Matters within [***] ([***]) days after written demand from an Indemnified Party plus a reasonable period of time for Tenant’s investigation of the claim.  Tenant shall also defend, with counsel reasonably satisfactory to the Indemnified Party, at Tenant’s sole expense, within [***] ([***]) days after written demand from the Indemnified Party, plus a reasonable period of time for Tenant’s investigation of the claim, any claims, action or proceeding arising out of or relating to an Indemnified Matter whether or not litigated or reduced to judgment and whether or not well founded.  This indemnity is intended to apply to the fullest extent permitted by applicable law.  Tenant’s obligations under this Section shall survive the expiration or termination of this Lease unless specifically waived in writing by Landlord after said expiration or termination.  Except in connection with liabilities, obligations, and claims pursuant to Sections 17 and 28 herein, Landlord hereby waives its right to recover consequential, special, indirect, exemplary or punitive damages (including but not limited to, lost profits) arising out of an Indemnified Matter. 

 

(B)         Subject to the terms of Section 10, and except to the extent caused by the negligence or willful misconduct of a Tenant Indemnified Party, Landlord hereby agrees to indemnify, defend and hold harmless Tenant and its employees, affiliates and agents (said persons and entities are hereinafter collectively referred to as the “Tenant Indemnified Parties”) from and against any and all Damages that result from (i) the negligence or intentional misconduct of Landlord its employees and its authorized representatives (ii) Landlord’s failure to perform any of its obligations under the Lease (which failure continues after the passage of any applicable notice and cure period under the Lease), and (iii) any other matters for which Landlord has agreed to indemnify Tenant pursuant to any other provision of this Lease (a “Tenant Indemnified Matter”).  Landlord’s obligations hereunder shall include, but shall not be limited to (a) compensating the Tenant Indemnified Parties for Damages arising out of Tenant Indemnified Matters within [***] ([***]) days after written demand from a Tenant Indemnified Party plus a reasonable period of time for Landlord’s investigation of the claim and (b) providing a defense, with counsel reasonably satisfactory to the Tenant Indemnified Party, at Landlord’s sole expense, within [***] ([***]) days after written demand from the Tenant Indemnified Party plus a reasonable period of time for Landlord’s investigation of the claim, of any claims, action or proceeding arising out of or relating to an Tenant Indemnified Matter. This indemnity is intended to apply to the fullest extent permitted by applicable law. Landlord’s obligations under this section shall survive the expiration or termination of this Lease unless specifically waived in writing by Tenant after said expiration or termination.  Tenant hereby waives its right to recover consequential, special, indirect, exemplary or punitive damages (including but not limited to, lost profits) arising out of a Tenant Indemnified Matter.

 

18

 

 

16.         UTILITIES.  Tenant shall contract directly with public utility providers for all utilities which are separately metered to the Premises and shall pay such utility providers directly and promptly when due.  If any utility is not separately metered to the Premises, the cost of such utility consumed on the Premises, as reasonably determined by Landlord, shall be paid by Tenant as a part of Operating Expenses.  Tenant’s obligation to pay for utilities provided to the Premises during the Term shall survive the expiration or earlier termination of the Lease.  Tenant shall not utilize an alternative provider for a utility service other than the public utility provider servicing the Property unless Tenant shall first obtain the written consent of Landlord.  Landlord shall not be liable or responsible for any loss, damage, or expense that Tenant may sustain or incur by reason of any change, failure, interruption, or defect in the supply or character of the electric energy furnished to the Premises or Building by the applicable utility provider.  To ensure the proper functioning and protection of all utilities, Tenant agrees to abide by all reasonable regulations and requirements which Landlord may prescribe and to allow Landlord and its utility providers’ access to all electric lines, feeders, risers, and wiring within the Premises.

 

Notwithstanding the provisions of this Section 16, in the event the Building experiences an interruption of electrical, telephone, HVAC or water service, which in any such case prevents Tenant from utilizing the Premises (or portion thereof) to conduct its business (a “Service Failure”) which Service Failure is due to Landlord’s actions (i.e. not as a result of the inability of Landlord to obtain the applicable utility service through no fault of Landlord (a “Controllable Service Failure”), Landlord shall commence and diligently pursue the curative action within a commercially reasonable amount of time after written notice from Tenant of a Controllable Service Failure.  Notwithstanding the foregoing, if Tenant does not conduct business in the Premises (or portion thereof) as a result of a Controllable Service Failure, Tenant shall be entitled to an equitable abatement of Rent (in proportion to the portion of the Premises subject to the Service Failure) with respect to a Controllable Service Failure commencing with the [***] ([***]) consecutive business day after Tenant’s notice to Landlord of the Controllable Service Failure until such time as the services are restored and/or the applicable repair is made, as the case may be.

 

19

 

 

17.         HOLDING OVER.  If Tenant or any party claiming by or under Tenant remains in occupancy of the Premises or any part thereof beyond the expiration or earlier termination of this Lease, such holding over shall be without right and a tenancy at sufferance, and Tenant shall be liable to Landlord for any actual loss or damage incurred by Landlord as a result thereof, including consequential damages, provided that in the case of consequential damages Landlord has first provided Tenant with at least [***] ([***]) days prior written notice that Landlord is obligated to deliver the space to a bona fide new tenant and that Landlord’s failure to deliver the space to such new tenant could result in consequential damages.  In addition, for each month or any part thereof that such holding over continues, Tenant shall pay to Landlord a monthly fee for the use and occupancy of the Premises equal to [***] percent ([***]%) of the Base Rent payable for the month immediately preceding such hold over, plus all Additional Rent due hereunder and there shall be no adjustment or abatement for any partial month.  The provisions of this section shall not be deemed to limit or exclude any of Landlord’s rights of re-entry or any other right granted to Landlord hereunder, at law or in equity.

 

18.         NO RENT DEDUCTION OR SET OFF.  Tenant’s covenant to pay Rent is and shall be independent of each and every other covenant of this Lease.  Tenant agrees that any claim by Tenant against Landlord shall not be deducted from Rent nor set off against any claim for Rent in any action except as expressly permitted under this Lease.  No payment by Tenant or receipt by Landlord of a lesser amount than the Rent herein stipulated shall be deemed to be other than on account of the earliest stipulated Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of such Rent or pursue any remedy provided in this Lease or at law.  In connection with the foregoing, Landlord shall have the absolute right in its sole discretion to apply any payment received from Tenant to any account or other payment of Tenant then not current and due or delinquent.

 

19.         CASUALTY.  If the Premises or any part thereof are damaged by fire or other casualty, Tenant shall give prompt notice thereof to Landlord.  If the Premises or the Building are totally or partially damaged or destroyed by fire or other casualty, thereby rendering the Premises totally or partially inaccessible or unusable, Landlord shall diligently restore and repair the Premises and the Building to substantially the same condition they were in prior to such damage.  Until the repair and restoration of the Premises is completed, Rent shall be abated for that part of the Premises that Tenant is unable to use and is not occupied while repairs are being made, based on the ratio that the amount of unusable rentable area bears to the total rentable area of the Premises.  Landlord shall bear the costs and expenses of repairing and restoring the Premises and the Building, provided, however, that Landlord shall not be obligated to spend more than the net proceeds of insurance proceeds made available for such repair and restoration nor shall Landlord be obligated to repair or restore, or to pay for the repair or restoration of, any furnishings, equipment or personal property belonging to Tenant.  It shall be Tenant’s sole responsibility to repair and restore all such items.

 

Notwithstanding the foregoing, (a) if there is a destruction of the Building that exceeds [***] percent ([***]%) of the replacement value of the Building from any risk, whether or not the Premises are damaged or destroyed, or (b) if Landlord reasonably believes that the repairs and restoration cannot be completed despite reasonable efforts within [***] ([***]) days after the occurrence of such damage, or (c) if Landlord reasonably believes that there shall be less than [***] ([***]) year remaining in the Term (exclusive of any extension options) upon the substantial completion of such repairs and restoration, or (d) if any mortgagee or lender fails or refuses to make sufficient insurance proceeds available for repairs and restoration, or (e) if zoning or other applicable laws or regulations do not permit such repairs and restoration, Landlord shall have the right, at its sole option, to terminate this Lease by giving written notice of termination to Tenant within [***] ([***]) days after the occurrence of such damage.  If this Lease is terminated pursuant to the preceding sentence, all Rent payable hereunder shall be apportioned and paid to the date Tenant was unable to occupy and ceased operations in the Premises.

 

20

 

 

Notwithstanding the foregoing, (a) if there is a destruction of the Building that exceeds [***] percent ([***]%) of the replacement value of the Building from any risk, and Tenant’s use of the Premises or the Common Areas are materially adversely impacted, or (b) if Landlord reasonably believes that the repairs and restoration cannot be completed despite reasonable efforts within [***] ([***]) days after the occurrence of such damage, and Tenant’s use of the Premises or the Common Areas are materially adversely impacted, or (c) if Landlord reasonably believes that there shall be less than [***] remaining in the Term (exclusive of any extension options) upon the substantial completion of such repairs and restoration, and Tenant’s use of the Premises or the Common Areas are materially adversely impacted, or (d) if the Premises or Common Areas are damaged or destroyed and any mortgagee or lender fails or refuses to make sufficient insurance proceeds available for repairs and restoration, or (e) if zoning or other applicable laws or regulations do not permit such repairs and restoration, then Tenant shall have the right, at its sole option, to terminate this Lease by giving written notice of termination to Landlord within [***] ([***]) days after the occurrence of such damage.  If this Lease is terminated pursuant to the preceding sentence, all Rent payable hereunder shall be apportioned and paid to the date Tenant was unable to occupy and ceased operations in the Premises.

 

If neither party elects to terminate this Lease and Landlord commences to restore the Building but does not substantially complete the repair and restoration of the Building within [***] ([***]) days following the date of casualty, then Tenant may terminate this Lease upon written notice to Landlord as of the end of such [***] ([***]) day period by providing written notice to Landlord, such termination to be effective [***] ([***]) days after notice from Tenant is received by Landlord, unless Landlord substantially completes the repairs within such [***] ([***]) day period upon which the Tenant’s termination shall be vitiated and the Lease shall continue in full force and effect.

 

In the event of any damage or destruction to the Building or Premises, it shall be Tenant’s responsibility to secure the Premises and, upon notice from Landlord, to remove forthwith, at its sole cost and expense, property belonging to Tenant or its licensees from such portion of the Premises as Landlord shall request.

 

20.          SUBORDINATION; ESTOPPEL LETTERS.  This Lease is expressly subject and subordinate to any current or future mortgage or mortgages placed on the Property and to all other documents executed in connection with any such mortgage.  Tenant agrees that from time to time it shall deliver to Landlord or Landlord’s mortgagee or designee within ten (10) business days of the date of Landlord’s or Landlord’s mortgagees or such other designee’s request, a statement, in writing, certifying (i) that this Lease is unmodified and in full force and effect, if this is so, or if there have been modifications, that the Lease, as modified, is in full force and effect; (ii) the dates to which Rent and other charges have been paid; (iii) that Landlord is not in default under any provisions of this Lease or, if in default, the nature thereof in detail; and (iv) such other true statements as Landlord or Landlord’s mortgagee or designee may reasonable require.  Tenant’s failure to execute and deliver such statements within the time required shall, at Landlord’s election, be an Event of Default and shall also be conclusive upon Tenant that (a) this Lease is in full force and effect and has not been modified except as represented by Landlord; (b) that Landlord is not in default under any provisions of this Lease and that Tenant has no right of offset, counterclaim or deduction against Rent.

 

21

 

 

Notwitstanding
the foregoing, Landlord will obtain a subordination, non-disturbance and attornment agreement in the form attached hereto as Exhibit H
(the “SNDA”) executed by Landlord and the current mortgagee, and Tenant shall execute and deliver such SNDA concurrently
with Tenant’s execution and delivery of this Lease and until the Full Premises Commencement Date, Landlord shall obtain
a subordination/non-disturbance and attornment agreement from any future mortgagee on such mortgagee’s standard form, subject
to Tenant’s reasonable comments.  After the occurrence of the Full Premises Commencement Date and upon Tenant’s
request, Landlord agrees to use reasonable efforts to have any mortgagee of the Property enter into its usual subordination, non-disturbance
agreement with Tenant provided that Tenant is not then in default under this Lease.

 

21.           ALTERATIONS; RESTORATION.

 

(A)          Tenant shall not make or permit to be made any alterations, additions, or improvements in or to the Premises (“Alterations”) without first obtaining the prior written consent of Landlord which consent shall not be unreasonably withheld, conditioned or delayed, provided any Alterations that may impact the structural portions of the Building or any mechanical systems shall be in Landlord’s sole discretion.  All Alterations (i) must comply with all applicable laws, (ii) must be compatible with the Building and its mechanical, electrical, heating, ventilating, air-conditioning and life safety systems; (iii) must not interfere with the use and occupancy of any other portion of the Building by any other tenant or their invitees; and (iv) must not affect the integrity of the structural portions of the Building.  In addition, Landlord may impose as a condition to such consent such additional requirements as Landlord in its sole discretion deems necessary or desirable, including, without limitation:  (a) Tenant’s submission to Landlord, for Landlord’s prior written approval, of all plans and specifications relating to the Alterations; (b) Landlord’s prior written approval of the time or times when the Alterations are to be performed; (c) Landlord’s prior written approval of the contractors and subcontractors performing work in connection with the Alterations; (d) Tenant’s receipt of all necessary permits and approvals from all governmental authorities having jurisdiction over the Premises prior to the construction of the Alterations; (e) Tenant’s delivery to Landlord of such bonds and insurance as Landlord customarily requires; (f) Tenant’s payment to Landlord of a commercially reasonable fee for Landlord’s supervision of any Alterations; (g) Tenant’s and Tenant’s contractor’s compliance with such construction rules and regulations and building standards as Landlord promulgates from time to time; and (h) Tenant’s delivery to Landlord of “as built” drawings of the Alterations in such form or medium as Landlord may reasonably require.  All direct and indirect costs relating to any modifications, alterations or improvements of Building, whether outside or inside of the Premises, required by any governmental agency or by law as a condition or as the result of any Alteration requested or effected by Tenant shall be borne by Tenant.  Tenant shall not permit any mechanic’s lien or other liens to be placed upon the Premises or the Building as a result of any materials, services or labor ordered by or provided to Tenant or any of Tenant’s agents, officers, or employees.  Without waiving any other rights or remedies under this Lease, Landlord may bond or insure or otherwise discharge any such lien and Tenant shall reimburse Landlord for any amount paid by Landlord in connection therewith as Additional Rent within [***] ([***]) days after Landlord’s written demand.

 

22

 

 

(B)          Upon the expiration or earlier termination of the Lease, Tenant shall surrender the Premises in good working order and condition, reasonable wear and tear and damage by casualty or condemnation excepted.  Tenant shall remove any trade fixtures, equipment, data/telecommunica­tions cabling and wiring installed by or on behalf of Tenant and furniture from the Premises and Tenant shall fully repair any damage, including any structural damage, occasioned by the removal of the same.  Notwithstanding the foregoing, Landlord may require that Tenant not remove any or all Alterations and any such Alteration or Alterations shall become a part of the realty and shall belong to Landlord without compensation, and title thereto shall pass to Landlord under this Lease as by a bill of sale.  At the time Tenant requests approval for an Alteration, Tenant may request that Landlord also provide consent for such Alteration to remain upon expiration of the Term, with Landlord not to unreasonably withhold consent thereto, and if Landlord consents (i) to the Alteration, and (ii) for the Alteration to remain, Tenant shall not be required to remove the Alteration in accordance with the terms of the Lease upon expiration of the Term.  At Landlord’s election, all Alterations, trade fixtures, equipment, wire and cable, furniture, fixtures, other personal property not removed shall conclusively be deemed to have been abandoned by Tenant and may be appropriated, sold, stored, destroyed or otherwise disposed of by Landlord without notice to Tenant or to any other person and without obligation to account for them.  Tenant shall pay Landlord all reasonable expenses incurred in connection with Landlord’s disposition of such property, including without limitation the cost of repairing any damage to the Building or the Premises caused by removal of such property, and shall hold Landlord harmless from loss, liability, or expense arising from the claims of third parties such as Tenant’s lenders whose loans are secured by such property.  Tenant’s obligations under this section shall survive the end of this Lease.

 

(C)          The interest of Landlord in the Premises shall not be subject in any way to any liens, including construction liens, for improvements to or other work performed in the Premises by or on behalf of Tenant.  Tenant shall have no power or authority to create any lien or permit any lien to attach to the present estate, reversion, or other estate of Landlord in the Premises or in the Property and all mechanics, materialmen, contractors, artisans, and other parties contracting with Tenant or its representatives or privies as to the Premises or any part of the Premises are charged with notice that they must look to Tenant to secure payment of any bill for work done or material furnished or for any other purpose during the Lease term.  These provisions are made with express reference to Section 713.10, Florida Statutes.  Landlord and Tenant acknowledge and agree that there is no requirement under this Lease that Tenant make any alterations or improvements to the Premises.  Tenant shall notify every contractor making improvements to the Premises that the interest of Landlord in the Premises shall not be subject to liens for improvements to or other work performed in the Premises by or on behalf of Tenant.  In the event that a construction claim of lien is filed against the Property in connection with any work performed by or on behalf of Tenant, Tenant shall satisfy such claim, or shall transfer same to security, within [***] ([***]) business days from the date that Tenant becomes aware of the same.  In the event that Tenant fails to satisfy or transfer such claim within said [***] ([***]) business day period, Landlord may do so and thereafter charge Tenant, as Additional Rent, all costs incurred by Landlord in connection with the satisfaction or transfer of such claim, including attorneys’ fees.  Further, Tenant agrees to indemnify, defend and save Landlord harmless from and against any damage or loss incurred by Landlord as a result of any such claim or lien. 

 

23

 

 

If so requested by Landlord, Tenant shall execute a short form or memorandum of this Lease, which may, in Landlord’s discretion be recorded in the Public Records for the purpose or protecting Landlord’s estate from construction claims of lien, as provided in Florida Statutes, Chapter 713.10.  No other memorandum of this Lease, nor this Lease itself shall be recordable in the public records of any county within the State of Florida without Landlord’s written consent and joinder, which may be arbitrarily withheld by Landlord in its sole discretion.  In the event such short form of Memorandum of Lease is executed, Tenant shall simultaneously execute and deliver to Landlord an instrument terminating Tenant’s interest in the real property upon which the Premises are located, which instrument may be recorded by Landlord at the expiration of the term of this Lease, or such earlier termination hereof.  The Security Deposit paid by Tenant may be used by Landlord for the transfer of any claim of lien, as provided in this Section.  This Section shall survive the termination of this Lease.

 

Notwithstanding the foregoing to the contrary, during the Term of this Lease, Tenant shall be permitted, with prior written notice to Landlord, but without Landlord’s prior written consent, to make non-structural interior alterations to the Premises costing in the aggregate not more than [***] Dollars ($[***]) in any [***] ([***]) month period, provided that such alterations (i) are not structural, (ii) do not affect the use or proper strengthening of any utilities, building systems, or other tenant spaces, (iii) are not visible from outside the Premises, (iv) do not include the penetration of the roof, and/or (v) do not require building permits.

 

22.         DEFAULT; REMEDIES.

 

(A)         In addition to any other acts or omissions designated in this Lease as Events of Default, each of the following shall constitute an Event of Default by Tenant hereunder:  (i) the failure to make any payment of Rent, Additional Rent or any installment thereof or to pay any other sum required to be paid by Tenant under this Lease within [***] ([***]) days after written notice for Landlord that such sum is due; (ii) the use or occupancy of the Premises for any purpose other than the Permitted Use without Landlord’s prior written consent or the conduct of any activity in the Premises which constitutes a violation of law; (iii) if the interest of Tenant or any part thereof under this Lease shall be levied on under execution or other legal process and said interest shall not have been cleared by said levy or execution within [***] ([***]) days from the date thereof; (iv) if any voluntary or involuntary petition in bankruptcy or for corporate reorganization or any similar relief shall be filed by or against Tenant or any guarantor of the Lease or if a receiver shall be appointed for Tenant or any guarantor or any of the property of Tenant or guarantor; (v) if Tenant or any guarantor of the Lease shall make an assignment for the benefit of creditors or if Tenant shall admit in writing its inability to meet Tenant’s debts as they mature; (vi) if any insurance required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as permitted in this Lease, or mutually agreed to in writing by the parties; (vii) if Tenant shall fail to discharge or bond over any lien placed upon the Premises as a result of Tenant’s actions in violation of this Lease; (viii) if any Letter of Credit required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as permitted in this Lease, or mutually agreed to in writing by the parties; (ix) if Tenant shall abandon or vacate the Premises during the Term and otherwise fail to comply with the terms of the Lease; (x) if Tenant shall fail to execute and deliver an estoppel certificate or subordination agreement as required hereunder; or (xi) the failure to observe or perform any of the other covenants or conditions in this Lease which Tenant is required to observe and perform and which Tenant has not corrected within [***] ([***]) days after written notice thereof to Tenant,  provided, however, that if the nature of Tenant’s non-performance is such that more than [***] ([***]) days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said [***] ([***]) day period and thereafter diligently and continuously pursues such cure to completion.

 

24

 

 

(B)         Upon the occurrence of an Event of Default by Tenant, Landlord may, at its option, with or without notice or demand of any kind to Tenant or any other person, exercise any one or more of the following described remedies, in addition to all other rights and remedies provided at law, in equity or elsewhere herein, and such rights and remedies shall be cumulative and none shall exclude any other right allowed by law:

 

(i)           Upon [***] ([***]) days written notice to Tenant, Landlord may terminate this Lease, repossess and re-let the Premises in accordance with Florida law, as the agent and for the account of Tenant upon such terms and conditions as Landlord may deem advisable or satisfactory, in which case Landlord shall be entitled to recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting.  For the purpose of determining present value, Landlord and Tenant agree that the interest rate shall be the rate applicable to the then-current yield on obligations of the U.S. Treasury having a maturity date on or about the Expiration Date.  Should the fair market rental value of the Premises for the balance of the Term (after deduction of all anticipated expenses of reletting) exceed the value of the Rent to be paid by Tenant for the balance of the Term, Landlord shall have no obligation to pay to or otherwise credit Tenant for any such excess amount;

 

(ii)         Landlord may, without terminating the Lease, terminate Tenant’s right of possession, repossess the Premises including, without limitation, removing all or any part of Tenant’s personal property in the Premises and to place such personal property in storage or a public warehouse at the expense and risk of Tenant, and relet the same for the account of Tenant for such rent and upon such terms as shall be satisfactory to Landlord.  For the purpose of such reletting, Landlord is authorized to decorate, repair, remodel or alter the Premises.  Tenant shall pay to Landlord as damages a sum equal to all Rent under this Lease for the balance of the Term unless and until the Premises are relet.  If the Premises are relet, Tenant shall be responsible for payment within [***] ([***]) days after Landlord’s written demand of any deficiency between the Rent as relet and the Rent for the balance of this Lease, all costs and expenses of reletting, and all reasonable decoration, repairs, remodeling, alterations, additions and collection of the rent accruing therefrom.  Tenant shall not be entitled to any rents received by Landlord in excess of the rent provided for in this Lease.  No re-entry or taking possession of the Premises by Landlord shall be construed as an election to terminate this Lease unless a written notice of such intention be given to Tenant or unless the termination thereof be decreed by a court of competent jurisdiction.  Notwithstanding any reletting without termination, Landlord may at any time thereafter elect to terminate this Lease for any breach, and in addition to the other remedies it may have, recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting.  In the event Landlord repossesses the Premises as provided above, Landlord may remove all persons and property from the Premises and store any such property at the cost of Tenant, and Tenant hereby waives any and all claims against Landlord for loss, destruction and/or damage or injury which may be occasioned by any of the aforesaid acts; and

 

25

 

  

(iii)        Landlord may, but shall not be obligated to, and without waiving or releasing Tenant from any obligations of Tenant hereunder, make any payment or perform such other act on Tenant’s part to be made or performed as provided in this Lease.  All sums so paid by Landlord and all necessary incidental costs shall be payable to Landlord as Additional Rent within [***] ([***]) days after Landlord’s written demand and Tenant covenants to pay such sums.

 

(C)         Tenant agrees that Landlord may file suit to recover any sums falling due under the terms of this section from time to time and that no suit or recovery of any portion due Landlord hereunder shall be any defense to any subsequent action brought for any amount not theretofore reduced to judgment in favor of Landlord.

 

(D)         Tenant shall promptly pay upon notice, as Additional Rent, all reasonable costs, charges and expenses incurred by Landlord (including, without limitation, reasonable fees and out-of-pocket expenses of legal counsel, collection agents, and other third parties retained by Landlord) together with interest thereon at the rate set forth in Section 5 of this Lease, in collecting any amount due from Tenant, enforcing any obligation of Tenant hereunder, or preserving any rights or remedies of Landlord. 

 

(E)         No waiver of any provision of this Lease shall be implied by any failure of Landlord to enforce any remedy on account of the violation of such provision, even if such violation be continued or repeated subsequently, and no express waiver by Landlord shall be valid unless in writing and shall not affect any provision other than the one specified in such written waiver and that provision only for the time and in the manner specifically stated in the waiver.  No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Term or Tenant’s right of possession hereunder or after the giving of any notice shall reinstate, continue or extend the Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of Rent shall not waive or affect said notice, suit or judgment.  Landlord shall not be required to serve Tenant with any notices or demands as a prerequisite to its exercise of any of its rights or remedies under this Lease, other than those notices and demands specifically required under this Lease. 

 

26

 

 

(F)         In the event of a breach or threatened breach by Tenant of any of the covenants or provisions hereof, Landlord shall have the right of injunction and the right to invoke any remedy allowed at law or in equity as if re-entry, summary proceedings and other remedies were not herein provided for.  Mention in this Lease of any particular remedy shall not preclude Landlord from any other remedy, in law or in equity.  Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or dispossessed for any cause, or in the event of Landlord obtaining possession of Premises by reason of the violation by Tenant of any of the covenants and conditions of this Lease, or otherwise.

 

23.         LANDLORD’S DEFAULT.  Landlord shall not be in default under this Lease unless Landlord fails to perform obligations required of Landlord within [***] ([***]) days after written notice by Tenant to Landlord and to the holder of any mortgage or deed of trust encumbering the Building whose name and address shall have theretofore been furnished to Tenant in writing, specifying wherein Landlord has failed to perform such obligation; provided, however, that if the nature of Landlord’s obligation is such that more than [***] ([***]) days are required for its cure, then Landlord shall not be in default if Landlord commences performance within such [***] ([***]) day period and thereafter diligently pursues the same to completion. In the event Landlord shall be in default under this Lease, Tenant may exercise any rights and remedies as provided for at law or in equity.

 

If Landlord fails to commence to cure any default by Landlord within the period provided in the paragraph above and if, as a result, Tenant is incapable despite commercially reasonable efforts to continue operations within the Premises, Tenant may give Landlord an additional written notice confirming that the default has not been cured and that Tenant intends to cure such default, and, if Landlord fails to cure such default within [***] ([***]) days after such notice, Tenant may take such steps within the confines of its Premises as are reasonably appropriate to cure the default and deduct the reasonable cost of such cure from the rent next coming due.  Tenant shall have no right to perform any obligation of Landlord in lieu of Landlord to the extent the same involves or may impact any base building system or any area of the Building outside of the Premises, including, without limitation, common areas or the premises of any other tenant or occupant of the Building.  Landlord’s liability to keep, maintain, and repair shall be limited to the cost of making such repair or accomplishing such maintenance or repair and Landlord shall in no case be liable for consequential or any indirect damages.  The provisions of this paragraph are subject to the provisions of Section 19 Casualty, Section 25 Eminent Domain, and Section 31(G) Force Majeure.

 

24.         NOTICES.  All notices permitted or required hereunder shall be in writing and (i) delivered personally, (ii) sent by U.S. certified mail, postage prepaid, with return receipt requested, or (iii) sent overnight by nationally recognized overnight courier and sent to the respective parties at the Notice Addresses provided in Section 1 of this Lease.  If sent by U.S. certified mail, such notice shall be considered received by the addressee upon receipt.  If sent by nationally recognized overnight courier, such notice shall be considered received by the addressee upon receipt.  Notices may be given by an agent on behalf of Landlord or Tenant. 

 

27

 

 

25.         EMINENT DOMAIN.  If during the Term (a) the whole of the Premises or the Building shall be taken by any governmental or other authority having powers of eminent domain or conveyed to such entity under threat of the exercise of such power or (b) any part of the Premises or the Building including parking or access to the Building shall be so taken or conveyed and as a result, the remainder of the Premises or the Building has been rendered impractical, in Landlord’s and Tenant’s mutual reasonable judgment, for the operation of Tenant’s business, this Lease shall terminate on the date of the taking or conveyance, and Rent shall be apportioned to the date thereof.  Any award for the taking of all or any part of the Premises or the Building under the power of eminent domain or any payment made under threat of the exercise of such power shall be the property of Landlord, whether such award shall be made as compensation for diminution in value of the leasehold, for good will, for the taking of the fee, as severance damages, or as damages for tenant improvements; provided, however, that Tenant shall be entitled to any separate award for loss of or damage to Tenant’s removable personal property and for moving expenses, provided it does not reduce the amount payable to Landlord.  In the event that this Lease is not terminated by reason of such condemnation, Landlord shall to the extent of severance damages received by Landlord in connection with such condemnation, repair any damage to the Building caused by such condemnation except to the extent that Tenant has been reimbursed therefor by the condemning authority. 

 

26.         QUIET ENJOYMENT.  Landlord represents and warrants that it has full right and authority to enter into this Lease and that Tenant, while paying the rental and performing its other covenants and agreements contained in this Lease, shall peaceably and quietly have, hold and enjoy the Premises for the Term without hindrance or molestation from Landlord subject to the terms and provisions of this Lease. 

 

27.         RULES AND REGULATIONS.  Tenant agrees to comply with (and cause its agents, contractors, employees and invitees to comply with) the rules and regulations attached hereto as Exhibit B and with such reasonable modifications thereof and additions thereto as Landlord may from time to time make and deliver to Tenant in writing.  Landlord agrees to enforce the rules and regulations uniformly against all tenants of the Property.  Landlord shall not be liable, however, for any violation of said rules and regulations by other tenants or occupants of the Building or Property.

 

28

 

 

28.         ENVIRONMENTAL.  “Environmental Laws” shall mean all federal, state, including but not limited to the Florida Department of Environmental Regulation or the Florida Department of Health, and local laws (including, without limitation, case and common law), statutes, regulations, rules, ordinances, guidance, permits, licenses, grants, orders, decrees and judgments relating to the environment, human health and safety.  “Hazardous Substances” shall mean all explosive materials, radioactive materials, hazardous or toxic materials, wastes, chemicals or substances, petroleum, petroleum by-products and petroleum products (including, without limitation, crude oil or any fraction thereof), asbestos and asbestos-containing materials, radon, lead, polychlorinated biphenyls, mold, urea-formaldehyde, and all materials, wastes, chemicals and substances that are regulated by any Environmental Law.  “Release” shall mean any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, or disposing of Hazardous Substances into the environment.  Tenant shall not (i) manufacture, generate, utilize, store, handle, treat, process, or Release any Hazardous Substances at, in, under, from or on the Premises or Property or (ii) suffer or permit to occur any violation of Environmental Laws with respect to the Premises or Property.  Tenant shall indemnify, defend (with counsel reasonably acceptable to Landlord and at Tenant’s sole cost) and hold harmless Landlord and its partners, managers, members, officers, directors, employees, agents, successors, grantees, assigns and mortgagees from any and all claims, demands, liabilities, damages, expenses, fees, costs, fines, penalties, suits, proceedings, actions, causes of action and losses of any and every kind and nature, including, without limitation, diminution in value of the Property, damages for the loss or restriction on use of the rentable or usable space or of any amenity, natural resource damages, damages arising from any adverse impact on leasing space on the Premises or Property, and sums paid in settlement of claims and for attorney’s fees, consultant’s fees and expert’s fees that may arise during or after the Term or any extension of the Term as a result of Tenant’s or Tenant’s agents, employees, contractors, assignees, subtenants, guests, invitees, or representatives introduction of any Hazard Substance to the property.  For purposes of this section, the term “costs” includes, without limitation, costs, expenses and consultant’s fees, expert’s fees and attorney’s fees incurred in connection with any investigation of site conditions or any cleanup, remedial, removal, restoration, monitoring or maintenance work.  This covenant of indemnity shall survive the termination of this Lease.  Notwithstanding the foregoing, the prohibition contained herein shall not apply to ordinary office products that may contain de minimis quantities of Hazardous Substances, provided such products are used in compliance with Environmental Laws; however, Tenant’s indemnification obligations are not diminished with respect to the presence of such products.  Tenant shall notify Landlord of any Release or threatened Release at, in, under, from, to or on the Premises or Property, promptly after Tenant become aware of the same.

 

To Landlord’s actual knowledge, as of the Effective Date, there are no Hazardous Substances in the Premises or the Building in violation of applicable law.  Notwithstanding anything contained in this Section 28 to the contrary, Tenant shall have no obligation under this Lease arising from or related to Hazardous Substances, unless such Hazardous Substances were introduced to the Premises or the Building by Tenant or Tenant’s agents, employees, contractors, assignees, subtenants, guests, invitees, or representatives. 

 

29.         INTENTIONALLY OMITTED. 

 

30.        BROKERS.  Tenant and Landlord each represent and warrant to the other that neither has had any dealings or entered into any agreements with any person, entity, broker or finder in connection with the negotiation of this Lease other than NAI Merin Hunter Codman, Inc., representing the Landlord, and Butters Realty and Management, representing the Tenant (the “Disclosed Brokers”).  No other broker, person, or entity is entitled to any commission or finder’s fee in connection with the negotiation of this Lease, and the party against whom a claim is made agrees to indemnify, defend and hold the other harmless from and against any claims, damages, costs, expenses, attorneys’ fees or liability for compensation or charges which may be claimed by any such unnamed broker, finder or other similar party by reason of any dealings, actions or agreements of the indemnifying party.  Landlord shall pay the Disclosed Brokers pursuant to the terms of a separate agreement.

 

29

 

 

 

31.          
MISCELLANEOUS.

 

(A)         
 Time is of the essence of this Lease and each
of its provisions.

 

(B)        
  This Lease and all covenants and agreements herein
contained shall be binding upon, apply, and inure to the respective heirs, executors, successors, administrators and assigns of
all parties to this Lease.

 

(C)        
  This Lease contains the entire agreement of the
parties, all other and prior representations, negotiations and agreements having been merged herein and extinguished hereby. 
No modification, waiver or amendment of this Lease or of any of its conditions or provisions shall be binding upon either party
hereto unless in writing signed by both parties.

 

(D)        
 The captions of sections and subsections of this
Lease are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such sections or subsections.

 

(E)        
  Interpretation of this Lease shall be governed
by the laws of the state or commonwealth in which the Premises is located, without regard to conflict of laws.  The parties
irrevocably submits to the nonexclusive jurisdiction of the courts of said state or commonwealth and agrees that all suits, actions,
claims or proceedings may be heard and determined in such courts.  The parties waive any objection which it may have at any
time to the laying of venue of any suit, action, claim or proceeding arising out of or relating to this Lease.

 

(F)        
  This Lease is and shall be deemed and construed
to be the joint and collective work product of Landlord and Tenant and, as such, this Lease shall not be construed against either
party, as the otherwise purported drafter of same, by any court of competent jurisdiction in order to resolve any inconsistency,
ambiguity, vagueness or conflict, if any, in the terms or provisions contained herein.

 

(G)        
  In the event that either party thereto shall
be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strikes, lock-outs, labor
troubles, inability to procure labor, inability to procure materials or equipment or reasonable substitutes therefore, failure
of power, fire or other casualty, restrictive government laws or regulations, judicial orders, enemy or hostile government actions,
riots, insurrection or other civil commotions, war or other reason of a like nature not the fault of the party delayed in performing
any act as required under the terms of this Lease (“Force Majeure”), then performance of such act shall be excused
for the period of delay and the period for the performance of any such act shall be extended for a period equivalent to the period
of such delay.  Force Majeure shall not operate to excuse either party from the prompt payment of Rent or any other payments
required under the terms of this Lease.

 

(H)        
 Tenant shall reimburse Landlord as Additional
Rent within [***] ([***]) days after Landlord’s written demand for all reasonable out-of-pocket expenses, including without
limitation legal, engineering or other professional services or expenses incurred by Landlord in connection with any requests
by Tenant for consents or approvals hereunder.

 

(I)         
  A final determination by a court of competent
jurisdiction that any provision of this Lease is invalid shall not affect the validity of any other provision, and any provision
so determined to be invalid shall, to the extent possible, be construed to accomplish its intended effect.

 

30

 

 

(J)           
If more than one person or entity shall ever
be Tenant, the liability of each such person and entity shall be joint and several.

 

(K)          
Each individual executing this Lease on behalf
of Tenant, represents and warrants that such individual is duly authorized to execute and deliver this Lease on behalf of Tenant,
that Tenant is duly authorized to enter into this Lease, and that this Lease is enforceable against Tenant in accordance with
its terms.  Each individual executing this Lease on behalf of Landlord, represents and warrants that such individual is duly
authorized to execute and deliver this Lease on behalf of Landlord, that Landlord is duly authorized to enter into this Lease,
and that this Lease is enforceable against Landlord in accordance with its terms.

 

(L)          
The submission of this Lease to Tenant is not
an offer to lease the Premises, or an agreement by Landlord to reserve the Premises for Tenant.  Landlord shall not be bound
to Tenant until Tenant has duly executed and delivered an original Lease to Landlord and Landlord has duly executed and delivered
an original Lease to Tenant.  Notwithstanding the Suite 160 Commencement Date or Full Premises Commencement Date contemplated
in Section 1 hereof, this Lease shall take effect and be binding upon the parties hereto as of its execution and delivery. 

 

(M)         
This Lease may be executed in any number of counterparts,
and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.  Any signature to this Lease transmitted via PDF or electronic signature shall
be deemed an original signature and be binding upon the parties hereto.

 

(N)          
Each party represents and warrants that neither
such party nor any of its members, shareholders or other equity owners, is a person or entity with whom U.S. persons or entities
are restricted from doing business under regulations of the Office of Foreign Asset Control (“OFAC”) of the Department
of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute, executive
order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit,
Threaten to Commit, or Support Terrorism), or other governmental action.

 

32.          
SOUTH FLORIDA COMMUTER SERVICE PROGRAMS.  The Property participates in programs promoted by regional commuter service
and other similar organizations designed and intended to maximize the people-moving capability of the transportation system, encourage
mass transit and manage transportation demand.  Information relating to such programs, including contact information for
the Employee Transportation Coordinator, is available at the main security desk as well as the mailroom/vending area of the Property.

 

33.          
CITY APPLICATION. 

 

(A)          
Prior to Tenant’s submission to the City of Boca Raton (the “City”) of an application (the “City Application”)
for a business tax receipt, certificate of use or any other item which requires any statement as to the use of the Premises (the
“Proposed Use”), Tenant shall deliver to Landlord a copy of the proposed City Application for Landlord’s prior
review to ensure the Proposed Use complies with the City’s zoning and other laws and regulations pertaining to the Premises. 
Landlord shall have the right to require Tenant to modify, amend or adjust the City Application prior to Tenant’s submission
of the City Application to the City.  Landlord’s approval of a City Application does not create any liability on the
part of Landlord and is merely being provided by Landlord to help ensure the City Application is properly submitted. 

 

31

 

 

(B)        
Each year during the Term, Tenant shall provide
Landlord with evidence that Tenant has timely and properly renewed its business tax receipt, certificate of use or other item
relating to the Proposed Use, within [***] ([***]) days of such renewal.  In connection with such renewal, Tenant agrees
not to modify, amend or adjust the Proposed Use in any manner.

 

(C)        
Tenant’s failure to comply with the terms
and provisions of this paragraph shall be an Event of Default and Landlord shall have any and all rights and remedies set forth
in Section 22 (Default; Remedies) hereof on account of such Event of Default.

 

34.          RADON GAS.  Radon is a naturally occurring
radioactive gas that, when it has accumulated in a building in sufficient quantities, may present health risks to persons who
are exposed to it over time.  Levels of radon that exceed federal and state guidelines have been found in buildings in Florida. 
Additional information regarding radon and radon testing may be obtained from your county public health unit.

 

35.          MOLD.  Mold is a naturally occurring
substance.  Mold is found both indoors and outdoors.  The presence of mold may cause property damage or health problems. 
Tenant acknowledges that it shall be Tenant’s responsibility to undertake necessary measures to retard and prevent mold
from accumulating within the Premises, including, but not limited to, the following: (i) maintaining appropriate climate control
within the Premises; (ii) maintaining the cleanliness of the Premises; (iii) removing visible moisture accumulations on windows,
window sills, walls, floors, ceilings and other surfaces as soon as reasonably possible; and (iv) not blocking or covering any
heating, ventilating or air conditioning ducts within the Premises.  Tenant shall report in writing to Landlord any evidence
of mold or of a water leak or excessive moisture within the Premises, promptly after Tenant becomes aware of same.  Should
Tenant desire a mold inspection or additional information about mold, Tenant should contact a professional in this field.

 

36.          PARKING. 
At all times during the Term (with the allocation of such spaces to be staggered based on the Suite 160 Commencement Date and
the Full Premsies Commencement Date), Tenant shall be entitled to the non-exclusive use of 281 parking spaces in the Building’s
parking lot or the shared lot (as shown on Exhibit A-3) (37 spaces as of the Suite 160 Commencement Date,
and the remaining 244 spaces as of the Full Premises Commencement Date).  As part of the overall parking allocation
(with the allocation of such spaces to be staggered based on the Suite 160 Commencement Date and the Full Premsies Commencement
Date) provided to Tenant herein (with the following parking to count towards Tenant’s 281 parking spaces), Landlord shall
provide forty-eight (48) covered spaces (6 covered spaces as of the Suite 160 Commencement Date, and the remaining 42 covered
spaces as of the Full Premises Commencement Date) at the locations identified on Exhibit A-1, at the initial rate
of $[***] per space, per month, with such rate to increase at the same time and at the same percentage increase as Base Rent. 
Landlord reserves the right to control the method, manner and time of parking in all parking spaces.  Tenant shall not use
any parking space designated by Landlord as visitor parking or as exclusive to other parties.  Tenant shall insure that its
employees, customers, clients, guests, invitees and licensees comply with the provision of this Section 36. If Tenant uses parking
in excess of that provided for herein, and if such excess use occurs on a regular basis, and if Tenant fails, after written notice
from Landlord of any one violation, to reduce its excess use of the parking areas, then Landlord may assess a charge of [***]
Dollars ($[***]) against the Tenant for each violation, which shall be payable as Additional Rent.  Further, Landlord reserves
the right to post a notice of violation on any offending vehicle and to tow the offending vehicle regardless of whether the vehicle
is owned by a Tenant or any other party, including any employee, customer, client, invitee or licensee of a Tenant, and to charge
the expense thereof to owner of the vehicle.

 

32

 

 

37.          SIGNAGE.  Tenant shall be entitled to
Building standard suite entry and directory signage.  Landlord may specify that the design of such signage be similar to,
or consistent with, the design and location of other signs identifying tenants in the Building.  Such signage shall be subject
to all applicable laws and ordinances. 

 

38.          RIGHT OF ENTRY.  Except in the event
of an emergency, Landlord shall only have the right to enter the Premises after first providing Tenant with at least twenty-four
(24) hours prior advance notice (which may be verbal) to Tenant.  Such entry shall only be permitted for purposes of allowing
Landlord to perform those acts required of or permitted to Landlord herein, including, without limitation, (i) the right to make
any repairs or replacements Landlord reasonably deems necessary, (ii) the right to show the Premises to prospective purchasers
and mortgagees, (iii) during the last twelve (12) months of the Term, the right to show the Premises to prospective tenants. 
Notwithstanding anything to the contrary contained in this Lease, no entry by Landlord or its agents or representatives shall
be made into or upon the Premises without the presence of an authorized employee of Tenant, except in a bona fide emergency not
permitting prior notification to Tenant. Tenant shall make an authorized employee available at reasonable hours to allow Landlord
to exercise its right to enter the Premises in accordance with the terms of this Section 38. It is understood that entry is being
restricted because of the nature of the business of Tenant requiring special security. In addition to the foregoing, except in
the event of a bona fide emergency or a specific request to acess such secure area in connection with an inspection by a governmental
authority, and provided that an authorized employee of Tenant accompanies the party entering into the secure area during such
emergency or governmental inspection, Tenant may prohibit Landlord from entering certain secure areas of the Premises as reasonably
determined by Tenant.  During any entry on to the Premises as permitted under this Section 38, Landlord and Landlord’s
agents and representatives shall comply with Tenant’s customary security procedures and shall use good faith efforts to
minimize any interference with Tenant’s operations at the Premises.

 

39.          CERTAIN RIGHTS RESERVED TO LANDLORD. 
Landlord reserves the following rights, and the exercise of any such rights shall not be deemed to constitute an eviction or disturbance
of Tenant’s use or possession of the Premises and shall not give rise to any claim for set-off or abatement of Rent or
any other claim provided that such rights do not adversely interfere with Tenant’s use of and operations at the Property:
(a) to enter the Premises for the purposes of examining the same or to make repairs or alterations or to provide any service;
(b) to change the arrangement and/or locations of entrances, or passageways, doors and doorways, and corridors, windows, elevators,
stairs, parking areas and any other common areas, (c) to change the name or street address of the Building or the suite number
of the Premises; (d) to install, affix and maintain any and all signs on the exterior or interior of the Building; (e) to make
repairs, decorations, alterations, additions or improvements, whether structural or otherwise, in, about and to the Building or
common areas and for such purposes temporarily close doors, corridors and other areas of the Building and interrupt or temporarily
suspend services or use of common areas; (f) to retain at all times, and to use in appropriate instances, keys to all doors within
and into the Premises; (g) to grant to any person or to reserve unto itself the exclusive right to conduct any business or render
any service in the Building; (h) if the Premises have been permanently vacated or abandoned by Tenant, to prepare the Premises
for re-occupancy; (i) to install, use and maintain in and through the Premises pipes, conduits, wires and ducts serving the Building;
(j) to approve the weight, size and location of safes or other heavy equipment or other articles which may be located in the Premises
and to determine the time and manner in which such articles may be moved in, about or out of the Building or Premises; and (k)
to take any other action which Landlord deems reasonable in connection with the operation, maintenance, marketing or preservation
of the Premises or Building.  The reduction or elimination of Tenant’s light, air or view shall not affect Tenant’s
liability under this Lease, nor shall it create any liability of Landlord to Tenant.

 

33

 

 

40.         
LEASE COMMENCEMENT/ACCEPTANCE OF PREMISES. 
At Landlord’s request, Landlord and Tenant shall enter into a commencement letter agreement (the “Commencement Letter”)
in form substantially similar to that attached hereto as Exhibit C once the Suite 160 Commencement Date has occurred
and once the Full Premises Commencement Date has occurred in accordance with the terms of Exhibit F.  Tenant’s
failure to execute and return the Commencement Letter, or to provide written objection to the statements contained in the Commencement
Letter, within [***] ([***]) days shall be deemed an approval by Tenant of the statements contained therein.

 

41.         
WAIVER OF RIGHT TO JURY TRIAL.  LANDLORD
AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM, ACTION, PROCEEDING OR COUNTERCLAIM BY EITHER PARTY AGAINST
THE OTHER ON ANY MATTERS ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, AND/OR
TENANT’S USE OR OCCUPANCY OF THE PREMISES OR BUILDING (INCLUDING ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY
REMEDY UNDER ANY CURRENT OR FUTURE LAWS, STATUTES, REGULATIONS, CODES OR ORDINANCES).

 

42.         
RECORDING.  Tenant shall not record
this Lease without the prior written consent of Landlord.  Tenant, upon the request of Landlord, shall execute and acknowledge
a short form memorandum of this Lease for recording purposes.

 

43.         
SUBORDINATION OF LANDLORD’S LIEN. 
Landlord hereby agrees to subordinate (on the form of agreement attached hereto as Exhibit J) any rights to a lien
(including statutory rights) on any of Tenant’s personal property located within the Premises to any purchase money lender.

 

44.         
NO RELOCATION.  Landlord waives any
right to relocate Tenant to any other space in the Building without first obtaining Tenant’s prior written consent, which
consent may be withheld by Tenant in its sole discretion.

 

[signatures
on following page]

 

34

 

 

IN
WITNESS WHEREOF, the parties hereto have executed this Lease. 

	 

	 

	 

	 

	 

	 

	LANDLORD:

	 

	TENANT:

	 	 	 
	951
YAMATO ACQUISITION COMPANY, LLC,
a Florida limited liability company

	 

	TherapeuticsMD,
Inc., a Nevada corporation

	 

	 

	 

	By:
BROOKWOOD YAMATO INVESTORS, LLC,
a Delaware limited liability company, its Sole
Member

	 

	 

	

	 

	By:

	/s/
Daniel Cartwright

	By:
BROOKWOOD YAMATO CO., LLC, a Delaware
limited liability company, its Manager

	 

	Name:

	Daniel
Cartwright

	 

	Its:

	CFO

 

	By:

	/s/
Kurt M. Zernich

	 

	Name:

	Kurt
M. Zernich

	 

	Its:

	Authorized
Signer

	 

	 

	 

	 

	WITNESS:     (2
witnesses required)

	 

	WITNESS:     (2
witnesses required)

	 

	 

	 

	/s/
Jennifer Johnson

	 

	/s/
John Milligan

	Witness
#1 Signature

	 

	Witness
#1 Signature

	 

	 

	 

	Jennifer
Johnson

	 

	John
Milligan

	Witness
#1 Print Name

	 

	Witness
#1 Print Name

	 

	 

	 

	/s/
Nicole Reeves

	 

	/s/
Lisa Maxwell

	Witness
#2 Signature

	 

	Witness
#2 Signature

	 

	 

	 

	Nicole
Reeves

	 

	Lisa
Maxwell

	Witness
#2 Print Name

	 

	Witness
#2 Print Name

 

35

 

 

EXHIBIT
A

 

THE
PREMISES

 

[***]

 

Exhibit A, Page 1

 

 

EXHIBIT
A-1

 

[Site
Plan for the Building]

 

[***]

 

Exhibit A-1, Page 1

 

 

EXHIBIT
A-2

 

[Location
of Parking Spaces]

 

[***]

 

Exhibit A-2, Page 1

 

 

EXHIBIT
A-3

 

[Building
Lot and Shared Lot]

 

[***]

 

Exhibit A-3, Page 1

 

 

EXHIBIT
B

 

RULES
AND REGULATIONS

 

[***]

 

Exhibit B, Page 1

 

 

EXHIBIT
C

 

FORM
OF COMMENCEMENT LETTER

 

[***]

 

Exhibit C, Page 1

 

 

EXHIBIT
D

 

ADDITIONAL
STIPULATIONS

 

[***]

 

Exhibit D, Page 1

 

 

Schedule
D-1

 

Tenant’s
Exterior Building Signage

 

[***]

 

Exhibit D, Page 2

 

 

Schedule
D-2

 

Tenant’s
Monument Signage

 

[***]

 

Exhibit D, Page 3

 

 

EXHIBIT
E

 

SUITE 160
WORK LETTER

 

[***]

 

Exhibit E, Page 1

 

 

Schedule
E-1

 

[Space
Plan for Suite 160 Work]

 

[***]

 

Exhibit E, Page 2

 

 

EXHIBIT
F

 

TENANT
IMPROVEMENTS LETTER

 

[***]

 

Exhibit F, Page 1

 

 

Schedule
F-1

 

[Suite
150 Space Plan]

 

[***]

 

Exhibit F, Page 2

 

 

Schedule
F-1

 

[Suite
220 Space Plan]

 

[***]

 

Exhibit F, Page 3

 

 

EXHIBIT
H

 

FORM
SNDA

 

[***]

 

Exhibit H, Page 1

 

 

EXHIBIT
I

 

ASSUMED
RENT TABLE

 

[***]

 

Exhibit I, Page 1

 

 

EXHIBIT
J

 

LANDLORD’S
AGREEMENT

 

[***]

Exhibit J, Page 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]